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ABSTRACT 
Considering the alarming rates at which substance drug abuse, especially cocaine, is increasing 
in today’s society, there is a lot of impetus on the development of medications that can 
effectively help alleviate its toxicity and addiction. The affinity of cocaine to sigma receptors 
(sigma-1 and sigma-2) rendered the hypothesis that blocking sigma receptors could be a possible 
mechanism to attenuate cocaine-induced toxicity and addiction. In this view, SN79, a synthetic 
compound with selectivity to both sigma-1 and sigma-2 receptors garnered our attraction for its 
use as an antagonist. This dissertation encompasses detailed investigation of SN79 from drug 
discovery and development perspective. Development and validation of a bio-analytical method 
using ultra performance liquid chromatography-mass spectrophotometry to selectively separate 
and identify SN79 in biological matrix was a crucial part of this project. Determination of 
various physicochemical parameters including aqueous solubility, chemical stability, Log P and 
pKa etc are presented. A number of in vitro tests necessary for predicting the compound’s profile 
in the body were also performed. Single dose pharmacokinetic studies were conducted in fasted 
and fed state rats that help determine the disposition of SN79 in vivo. 
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CHAPTER I: INTRODUCTION 
 
1.1  Substance Drug Abuse and Addiction 
 
Substance abuse and addiction is a major concern in today’s society. It is vital to address drug 
addiction considering the alarming rates at which people, especially teenagers, are drawing 
themselves towards drug abuse.  There are several categories of illicit drugs: hallucinogens, 
inhalants, tranquilizers, sedatives, prescription type pain relievers like hydrocodone and 
stimulants such as cocaine. The 2009 annual survey from National Survey on Drug Use and 
Health (NSDUH) in collaboration with Substance Abuse and Mental health Services 
Administration (SAMHSA) reported that an estimated 21.8 million Americans aged 12 or above 
were illicit drug users. This represents 8.7 percent of the population aged 12 or older are on any 
of the drug categories listed above [3]. In addition to the obvious health risks associated with 
some drugs, abuse can lead to higher risk behavior or amplify the course of existing problems. 
Some of the more common medical problems associated with drug abuse include cardiovascular 
disease, stroke, cancer, HIV/AIDS, hepatitis, and lung disease.  
Treatment statistics reflect the rising use of illicit drugs and prescription psychotherapeutics. 
According to a survey conducted by NSDUH in 2009, 23.5 million Americans (ages 12 and 
older) needed treatment for drug addiction of which only 2.6 million (1.0% of the population) 
received treatment [3]. Treatment for individual disorders was as follows: alcohol (2.9 million), 
marijuana (1.2 million), cocaine (787, 000), and heroin (507, 000 [3]. 
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Cocaine abuse and addiction continues to plague the society. About one in six Americans has 
tried cocaine by the age 30, and 7% of the population have tried it by their senior year of high 
school [4]. Cocaine is associated with the maximum number of emergency visits caused by illicit 
drugs [5]. The use of cocaine is correlated with medical and psychiatric morbidity. According to 
the Drug Abuse Warning Network (DAWN) system in 2002, approximately 200,000 people 
specified cocaine use in case of emergency medical or psychiatric treatment in emergency 
departments [6]. Most of the cases are cocaine coupled with ethanol or an opiate. Cocaine abuse 
can be treated with behavioral therapies. According to Carroll et al. [7], some patients respond 
well to behavioral treatments, while others continue to abuse cocaine with reduced frequency and 
still others drop out of treatment [8]. 
Current break-through discoveries regarding brain anatomy and other genetic studies provide 
unprecedented openings in combating this public health issue. In view of cocaine’s immense 
abuse potential, it is crucial to develop medications that can effectively help alleviate its toxicity 
and addiction. 
1.2 Cocaine 
1.2.1 History and Uses 
Cocaine, originally extracted from the Erythroxylon coca bush, was primarily found native in 
Peru and Bolivia [9]. It is well known that cocaine was used for panacea and local anesthetic 
effect in the Incan Empire of Peru. The leaves were first consumed by Aymara Indians of the 
Andes Mountains [9]. They chewed the leaves to help elevate mood, decrease hunger and 
increase their stamina for work [9]. In 1884, Karl Koller in Europe demonstrated its therapeutic 
potential [10]. He used its tissue-numbing capability to anaesthetize cornea of the eye [10]. The 
 next twenty years saw a steep rise in the use of cocaine to treat pain (physical and mental) in 
patients with terminal diseases. In 1879; it began to be used for the treat
addiction [11]. By 1885, cocaine was being marketed by the U.S. manufacturer Parke Davis in 
the form of cigarettes, powder and as a mixture to be administered intravenously
turn of the twentieth century, the addictive potential of cocaine became clear capturing public 
attention. On December 17, 1914, the Harrison Narcotics Tax Act was approved as a United 
States Federal law to illegalize the sale and distribution of 
Cocaine was not considered a controlled substance unti
Controlled Substances Act in 1970
drug under the Controlled Substances Act of 1970. This status categorizes it as a drug of high 
abuse potential but can be used legitimately in medical treatments
some eye, ear, and throat surgeries
Two chemical forms of cocaine are commonly available: the 
and the water-insoluble cocaine base (or freebase). The principal routes of administration are: 
oral, intranasal, intravenous and inhalation. The drug can also be rubbed on mucous tissues. Any 
route of administration can lead to absorption of toxic amounts of cocaine, possible acute 
cardiovascular or cerebrovascular emergencies, and seizures
death [4]. 
21 
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l the United States included it in the 
 [13]. Today, cocaine possesses the status of a Schedule II 
, such as local anesthesia for 
 [13]. 
water-soluble hydrochloride salt 
—all of which can result in sudden 
 
Figure 1.1 Cocaine 
 [12]. By the 
[5]. 
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1.2.2 Mechanism of Action 
Cocaine is believed to cause euphoric effects by acting on the reward circuitry in the brain. One 
possible explanation is that cocaine exerts major effects on parasympathetic,as well as 
sympathetic, function [9]. Through extensive research of the neuronal circuitry and 
neurochemistry, scientists have identified various regions in the brain stimulated by reinforcing 
stimuli such as food, sex and illicit drugs. One such neural system that is affected by cocaine is 
called Ventral Tegmental Area (VTA) that originates in a region of the midbrain. This region 
extends into one of the brain’s key areas involved in reward called nucleus accumbens [14].  The 
mesolimbic and mesocortical dopamine systems projecting from the VTA to the nucleus 
accumbens and frontal cortex have been found to have psychomotor stimulant reward function 
[15] (Figure 1.2).  
 
 
 
 
Figure 1.2 Certain regions of the brain are known to be involved in reward/reinforcement due to 
drugs. These include the nucleus accumbens (NA), ventral tegmental (VT) and frontal cortex (FC). 
Cerebellar (CB), putamen (PT) and caudate nucleus (CN) [1].  
Reproduced with kind permission from American Chemical Society Rightslink (License number: 
2640561044896)   
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Rewards are responsible for enhancing brain levels of dopamine, thereby increasing neural 
activity in the nucleus accumbens. When dopamine is released by a neuron into the synapse, it 
binds to specialized proteins (dopamine receptors) on the neighboring neuron thereby sending a 
signal to that neuron. Subsequently, dopamine is removed by dopamine reuptake transporter 
(DAT) from the synapse to be recycled for further use [16-17]. The rationale for selecting 
dopaminergic drugs to treat cocaine abuse and dependence is based on the dopamine hypothesis. 
According to the “Dopamine Hypothesis”, cocaine attaches to the dopamine reuptake 
transporters (DAT) thereby blocking the normal communication process [16]. This results in an 
accumulation of dopamine neurotransmitter in the synapse, which sends an amplified signal to 
the receiving neurons. This mechanism is what causes the “euphoria” associated with drugs of 
abuse [16, 18]. The increase in dopamine levels in the brain due to cocaine’s interaction with 
DAT is a critical element in cocaine’s reinforcing properties [1]. 
1.2.3 Scope of Pharmacotherapy 
The National Institute on Drug Abuse (NIDA) funds a broad variety of research focused on 
drugs of abuse and the causes and treatment of addictive disorders. Researchers have tried their 
best to develop anti-cocaine agents by blocking its primary site of action, DAT (Figure 1.3). In 
developing cocaine antagonists, several compounds were screened but most of them exhibited 
cocaine-like effects [1, 19]. In an experiment conducted on DAT knock-out mice, it was 
observed that the subjects had conditioned place preference to cocaine suggesting that cocaine 
had affinity to other sites [20]. It was established that cocaine also interacts with other 
neurotransmitter systems such as norepinephrine transporters (NET), serotonin transporters 
(SERT) and sodium ion channels [21-25].  
24 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Schematic representation of the dopamine hypothesis of cocaine’s reinforcing 
effects. (A) Stimulation of neuron releases DA from the presynaptic terminal into the 
synapse where it may bind to DA receptors on the postsynaptic terminal, resulting in 
transmission of signal; reuptake of DA via the transporter teriminates the action. (B) 
Cocaine blocks this reuptake of DA, flooding the synapse with excess DA thereby 
causing an enhanced signal. A direct competitive antagonist of cocaine would block 
cocaine binding but would not block dopamine [1]. 
Reproduced with kind permission from American Chemical Society Rightslink (License 
number: 2640561044896) 
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Efforts to develop therapeutic agents by blocking these previously identified sites did not yield 
satisfactory results characterized by low efficacy and undesirable side effects [1]. 
To develop a compound into a medication, the compound should possess certain properties. On 
careful perusal, the following characteristics have been listed as desirable in potential candidate 
compounds for cocaine abuse: 
• Must be potent and selective with minimal side effects [1]. 
• Must remain active following the desired route of administration [1]. 
• Must possess suitably long duration of action so as to allow for reasonable dosing 
schedules [26]. 
• Must enter the brain slowly owing to the fact that compounds entering the brain 
rapidly are associated with high abuse liability [27-29]. 
• Possess low potential for self-administration in animal models [1]. 
Table 1.1 lists the various animal behavioral models that are used in the development of 
medications for cocaine abuse [1]. Reproduced with kind permission from American 
Chemical Society Rightslink (License number: 2640561044896) 
Table 1.1. Animal Behavioral Models for Drug Screening  
Drug Self Administration 
Drug Discrimination 
Schedule-Controlled Responding 
Intracranial Self Stimulation (ICSS) 
Conditioned Place Preference 
Locomotor Activity 
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Similarly, table 1.2 lists several neurochemical assays that help identify potential 
compounds in the drug development process [1]. Reproduced with kind permission 
from American Chemical Society Rightslink (License number: 2640561044896) 
Table 1.2. Some Neurochemical/Neurophysiologic/Neuroanatomic Assays [30-35] 
Receptor binding 
In situ hybridization 
Receptor autoradiography 
Immunocytochemistry 
Microdialysis 
Voltametry 
Gene Cloning 
Antisense technology 
 
 
In 1996, Mello and Negus [36]recommended that an ideal medication for cocaine abuse 
should be capable of depressing the dose-response curve for cocaine self administration. This 
curve, typically in the form of an inverted “U” is presented in figure 1.4. A medication that 
depresses this “U” downward will be effective in decreasing cocaine-intake behavior over a 
broad range of doses. 
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Figure 1.4 Effect of medication in an ideal dose-response curve for cocaine in self-
administration studies. The typical dose-response is an inverted “U” [1, 36]. 
Reproduced with kind permission from American Chemical Society Rightslink (License 
number: 2640561044896) 
 In 1989, as per directives from the U.S. Congress, the NIDA Medications Development 
Program (MDP) initiated the drug development process to evaluate and develop medications 
for cocaine dependence [6]. To achieve this goal, the MDP worked independently as well as 
in conjunction with the pharmaceutical industry. The MDP used a top-down as well as 
bottom-up approach in the development of medications [6]. Some of these medications 
underwent clinical trials with some success noted but also associated with efficacy problems.  
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1.3 Dopamine System 
The drug screening sequence most commonly used in developing medications for cocaine related 
toxicity and addiction is receptor binding. Based on the strong recommendations received for the 
“dopamine hypothesis” [16, 37-39], research was largely focused on targeting cocaine’s access 
to dopamine transporters, its primary site of action. Various laboratory studies [40-43] showed 
that dopamine uptake inhibitors and direct-acting dopamine agonists could maintain drug self-
administration in laboratory animals. Some drug-discrimination studies suggested that certain 
dopamine uptake inhibitors substitute completely for cocaine [44-45] while the direct-acting 
dopamine agonists substitute partially for cocaine [46-47]. On the other hand, dopamine 
antagonists can attenuate specific behavioral effects of cocaine including its reinforcing effects 
[48-49], locomotor activity effects [50], discriminative stimulus effects [51-53] and rare-altering 
effects on schedule-controlled behavior [41, 54-56]. There are some promising results with a 
number of these dopamine agents but side effects such as abuse potential associated with these 
drugs limit their acceptability in drug abusers [1]. 
1.4 Serotonergic Drugs 
Owing to cocaine’s complex pharmacology, it has been found to interact with more than one 
neurotransmitter system [1]. Based on these findings, a broad range of drug classes have been 
studied in pre-clinical and clinical areas for their effectiveness in treatment of cocaine abuse. 
Wolf and Kuhn [57]reported that cocaine binds the serotonin (5HT) receptor with greater affinity 
than the dopamine receptor. Consistent with these results, administration of the 5HT uptake 
inhibitor, fluoxetine or the 5HT precursor, L-tryptophan decreases IV self-administration of 
cocaine in rats [58-60]. Conversely, several 5HT3-selective antagonists such as MDL 72222 and 
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ondansetron failed to block the reinforcing [61-62] or discriminative-stimulus effects [61, 63] of 
cocaine in laboratory animals.  
1.5 Excitatory and Inhibitory Amino Acids 
Reports also suggest that excitatory and inhibitory amino acid pathways may provide useful 
targets in the treatment of substance abuse [64-67]. Several N-methyl-D-aspartic acid (NMDA) 
noncompetitive antagonists, MK801 and SGB-017 and the competitive antagonist NPC 12626 
were examined in behavioral studies [68-71]. 
In addition, inhibitory amino acid systems such as γ-aminobutyric acid (GABA) are known to be 
widely distributed in the central nervous system (CNS) [72] and are also involved in the 
reinforcing effects of cocaine [64-67]. Baclofen, a GABAB receptor agonist that inhibits the 
release of dopamine, norepinephrine, serotonin and glutamate, was shown to suppress cocaine 
self-administration in rats [73]. Another candidate, vigabatrin, a GABA-transaminase (GABA-T) 
inhibitor also blocked cocaine self-administration [65, 74]. Vigabatrin is currently in human 
trials to examine its effectiveness in the treatment of cocaine abuse. Vigabatrin is on market in 
Europe for cocaine abuse and in the United States for partial seizures [75]. 
1.6 Opioid Receptor System 
Another neurotransmitter system linked to the pharmacology of cocaine is the endogenous opioid 
system. Naltrexone, an opioid antagonist showed no alteration to cocaine self-adminstration in 
laboratory animals [36]. Some δ-opioid receptor selective antagonists such as naltrindole and 
naltriben also showed inconsistent results in rats and rhesus monkeys [73, 76]. 
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The κ-selective agonists 50, 488, spiradoline [77], enadoline and bremazocine [78], κ-opioid 
receptor antagonist norbinaltorphimine [79] – all showed varied results in altering cocaine self-
administration in laboratory animals. 
1.7 Sigma Ligands 
In 1988, studies conducted by Sharkey et al. established the micromolar affinity of cocaine 
towards sigma receptors [80]. These receptors were initially viewed to be a part of opioid 
receptor family. They derive the name “sigma” from the first letter of the compound SKF-10047 
(N-allylnormetazocine) that was considered to be an archetype sigma ligand[81]. Owing to the 
irreversible effects of (+)-SKF-10047 by classic opioid antagonists like naloxone, sigma 
receptors were eliminated from the opioid class [82]. Further studies indicated that (-)-SKF-
10047 had an affinity for mu (µ) and kappa (κ) receptors. (+)-SKF-10047 exhibited affinity 
towards a different site from opioid receptors [83-85]. Investigations also revealed interactions of 
(+)-SKF-10047 with PCP sites affiliated to NMDA receptors [86-88]. Eventually, in 1988, Wong 
et al. discovered that (+)-SKF-10047 could not be displaced by very sensitive PCP/NMDA 
ligands [88]. Thus, this receptor site discrete from opioid and NMDA receptors was labeled as 
the sigma receptor. 
1.7.1 Sigma-1 and Sigma-2 
There are two subtypes of sigma receptors, namely sigma-1 and sigma-2 respectively [89]. Both 
of these subtypes are distinct in terms of molecular weight, distribution in the body and ligand 
binding profile [89-90]. Sigma-1 receptors have a molecular weight of 25-29 kDa and composed 
of 223 amino acids [91-94]. Sigma-2 receptors have a molecular weight of 18-22 kDa[95]. 
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Researchers have been able to clone sigma-1 receptors from mouse, rat, guinea pig and human 
tissues but no sigma-2 receptors have been cloned as of yet [79, 93, 96]. 
Sigma-1 and Sigma-2 receptors are extensively distributed in the body. They can be found in the 
brain, liver, gastrointestinal tract and kidney [95, 97]. Highest densities of sigma receptors are 
found in brainstem motor nuclei, cerebellum, red nucleus and in cranial nerves such as facial, 
hypoglossal and trigeminal nerves [98]. In the heart, approximately 80% of the sigma receptors 
are of the sigma-1 subtype and linked to many aspects of cardiovascular function [99]. 
In comparison to the research conducted on sigma-1 subtype antagonists, work indicating the 
involvement of sigma-2 receptors in cocaine-induced effects is nominal. This is attributed to the 
fact that sigma-2 receptors have not yet been cloned and there are no antisense oligonucleotides 
(ON) to reduce their number. Therefore, it is important to study the pharmacological and 
toxicological profile of compounds specific to sigma-1 and sigma-2 subtypes to aid in 
identifying the most effective compounds for treatment of drug abuse. 
1.8 Sigma Receptors 
Ever since Michael Kuhar et al. [16] discovered the micromolar affinity of cocaine for sigma 
receptors (σ), much attention has been given for further investigation of this new site. Sigma 
receptors have been implicated in many neuropsychiatric disorders as well as schizophrenia, 
seizures and anxiety [80]. Contrary to initial beliefs, this class of receptors was declared 
distinctly different from the opioid and NMDA receptors [81-88]. Sigma receptors are 
distributed extensively in the brain and peripheral organs [95, 97-98]. They are also expressed 
throughout the central nervous system.  
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1.8.1 Subtypes of Sigma Receptors 
Sigma receptors have been classified into two main subtypes, sigma-1 (σ-1) and sigma-2 (σ-2) 
[89]. These subtypes were differentiated based on their molar mass, expression throughout 
various tissues, different drug selectivity patterns and ligand binding profile [89-90] (Table 1.3). 
Table 1.3 Subtypes of Sigma Receptors [2] 
Characteristics Sigma-1 Receptor Sigma-2 Receptor 
Molecular Weight 25-29 kDa 18-22 kDa 
Tissue Distribution 
Brain, heart, liver, spleen, 
gastrointestinal tract 
Brian, liver, gastrointestinal 
tract 
Relative affinity of 
benzomorphans 
(+)-isomer (-)-isomer 
 
1.8.2 Sigma-1 (σ-1) Receptor Subtype 
The sigma-1 receptors found to be discrete from the opioid receptors [83-88] reside specifically 
at the endoplasmic reticulum (ER)-mitochondrion interface called the MAM (mitochondrion-
associated ER membrane) [100]. Sigma-1 receptors have been cloned and well characterized due 
to the availability of selective sigma-1 ligands. The sigma-1 receptor cDNA has been cloned 
from guinea-pig liver, human placental cell line, T leukemia Ichikawa cell line and human brain, 
mouse kidney and brain, and rat brain [101]. It consists of 223 amino acids and the sequences of 
the purified proteins have been found to be highly similar. The protein sequence also showed 
similarity, a 33% identity and 66% homology, with a yeast sterol C8-C7isomerase [79]. However, 
no similarity has been observed with any mammalian enzyme or any other mammalian protein, 
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indicating that it is a unique receptor from any other existing receptors [101]. Their anatomical 
distribution has been well established based on initial auto-radiographic studies in rodent brain 
and more recently using in situ hybridization or immuno-histochemical techniques. They are 
understood to be concentrated in specific areas throughout limbic systems and brainstem motor 
structures [101]. Its presence is dense in the granular layer of different structures such as 
olfactory bulb, hypothalamic nuclei and hippocampus [102-103]. This receptor is particularly 
concentrated with post-synaptic thickenings, although can be observed at the pre-synaptic level. 
It contains an endoplasmic reticulum sequence, which upon activation translocates the sigma-1 
receptor from the endoplasmic reticulum to the plasma or nuclear membrane [104-105]. The 
sigma-1 receptor is also widely expressed throughout the peripheral organs such as the digestive 
tract [106-107], vas deferens [108-109], liver [95, 108, 110], kidney [111], heart [112], adrenal 
medulla [113-114], pituitary testis and ovaries [113-115] and blood mononuclear cells [114]. The 
subcellular distribution profile of [3H](+)-SKF-10,047 of the radioligand binding to sigma-1 sites 
coincided with that of NaDPHcytochrome c reductase, indicating the presence of sigma-1 
receptor on the endoplasmic reticulum [101]. Sigma-1 receptors have been shown to play an 
important part in regulation of cardiac function by exerting a complex effect on the amplitude 
and frequencies of contraction, Ca2+ fluxes and intracellular Ca2+ concentration transients [112]. 
In particular, sigma-1 receptor agonists such as DTG, (-)-3-PPP, (+)-pentazocine, or BD737 
increase the electrically-evoked amplitude of the contraction and Ca2+ transients [99, 112]. DuP 
734, a sigma-1 receptor antagonist reversed the decrease in ventricular fibrillation threshold 
induced in conditions like post-infarction cardiosclerosis or immobilization stress [99]. 
Sigma-1 receptors are found to be highly mobile at the ER membrane suggesting a chaperone 
action [100, 116]. The mechanism of translocation is however unknown. 
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• Translocation of sigma-1 receptors has been observed from the ER to the neurite process 
and the nucleus when NG108 cells were treated with cocaine [117-118].  
• Another example includes translocation of sigma-1 receptors from the MAM following 
loss of glucose or deficiency of ER Ca2+ by thapsigargin [100].  
• Presence of a sigma-1 receptor agonist, (+) pentazocine caused the sigma-1 receptors to 
translocate from lipid raft fractions to non-raft fractions [117, 119]. 
It is perceived that ligand or stress induced translocation of sigma-1 receptors might change their 
target proteins from those at MAM to others at the plasmalemma or nuclear envelopes [120]. In 
mouse, these receptors were found to regulate voltage gated potassium channels in posterior 
pituitary nerve terminals [91]. In rats, sigma-1 receptors modulate various Ca2+ channels in 
sympathetic and parasympathetic neurons [104, 121]. This ability of sigma-1 receptors to act as 
an inter-organelle signaling modulator can be potentially used to develop medications for 
peripheral diseases as well as those related to central nervous system [120]. 
Considering the concentration of sigma-1 receptors in peripheral organs mediating physiological 
and behavioral effects at pharmacologically relevant doses, it is of immense interest in cocaine 
addiction. Cocaine is known to act not only on the brain, but also in tissues such as heart, lung, 
digestive tract and kidney. In cases of overdose or toxicity, peripheral sigma-1 receptors may 
influence the effects of cocaine. 
1.8.3 Sigma-2 (σ-2) Receptor Subtype 
Sigma-2 receptors have a molecular weight of 18-22 kDa, which is less than that of sigma-1 
receptors [95]. Unlike sigma-1 receptors, these receptors have not yet been cloned. These 
receptors are found to be densely located in parts of the brain associated with motor activity like 
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the substantia-nigra pars reticulate, central gray matter, occulomotor nuclei, cerebellum and 
motor cortex [98]. In the peripheral organs, their presence is less dominant compared to that of 
sigma-1 receptors in heart and spleen [99]. The literature is abundant in reports on sigma-2 
ligands[122-130]. Most of these reports are based on the reasonable affinity to sigma-2 receptor 
relative to sigma-1, with little emphasis on selectivity as compared to non-sigma binding sites. 
Functional studies conducted by Bowen et al and other researchers have shown that few sigma-2 
compounds that were tested behaved like agonists [123-124, 131-132]. On the other hand, (±)-
SM 21 (3α-tropanyl-2-(4-chlorophenoxy) butyrate), a sigma-2 preferring compound has been 
shown to exhibit antagonist activity against dystonic head movements and cocaine-induced 
behaviors in rodents [133-134]. Sigma-2 receptors have also been implicated in tumor cell 
proliferation [135-137]. It has been suggested that sigma-2 receptors induce apoptosis by causing 
depletion of cytoplasmic Ca2+ stores resulting in subsequent cell death [138]. Sigma-2 receptors 
have also been linked to potassium channels and intracellular calcium release in NCB-20 cells 
[79]. Selective sigma-2 ligands such as CB64D, CB184 and ibogaine and non-selective sigma-2 
ligands such as haloperidol have been shown to affect growth and cause cell death in various 
tumor cell lines [138-140].  
One of the hindrances in evaluating the profile of sigma-2 receptors is the lack of selective 
pharmacological sigma-2 antagonists and an amino acid sequence from which antisense 
oligonucleotides with sigma-2 selectivity can be developed. Of the two characterized subtypes, 
there is sufficient evidence reflecting the role of sigma-1 receptors in attenuating cocaine-related 
effects but the contributions of sigma-2 receptors are less clear. 
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1.9 Drug development targeting Sigma ligands 
The discovery of cocaine’s interaction with sigma-receptors opened new possibilities for 
research involving the development of suitable medications for cocaine-induced toxicity and 
addiction [80]. Three different mechanisms were proposed to understand the influence of sigma 
receptors on the effects of cocaine – 1) direct binding to the receptors, 2) modulation of other 
neurotransmitter systems, and 3) alterations in gene expression [21, 141-144]. It was 
hypothesized that blocking these sigma receptors could help attenuate cocaine related effects.  
Certain non-selective sigma receptor antagonists such as BD1008 (N-[2-(3, 4-dichlorophenyl) 
ethyl]-N-methyl-2-(1-pyrrolidinyl) ethylamine) and its analogs successfully mitigated cocaine-
induced toxic effects like convulsions and lethality in some cases [145-148].  
Rimcazole (9-[3-(cis 3, 5-dimethyl-1-piperazinyl) propyl] carbazole), known as an “atypical 
antipsychotic” was found to lessen convulsions, locomotor stimulatory activity and sensitization 
in mice treated with cocaine [149-151]. Some synthetic analogs of rimcazole were also reported 
to have the same effect as rimcazole on cocaine-administered mice [149, 152-153].  Despite the 
dual affinity of rimcazole and its analogs towards both sigma-receptors and dopamine 
transporters (DAT), it was believed that the mitigation of cocaine induced effects correspond to 
their affinity for the sigma receptor [149]. 
In vitro studies conducted on AC927 (phenethylpiperidine), a compound with mixed sigma1/2 
affinity, were found to have antagonist actions through sigma-2 receptors [131]. Among its 
analogs, UMB24 (1-(2-phenethyl)-4-(2-pyridyl)-piperazine) was identified as a lead compound 
for development of selective sigma-2 receptor agents [127]. Behavioral studies in mice showed 
 that pretreatment with UMB24 resu
locomotor activity but not lethality 
Recently, CM156 (3-(4-(4-cyclohexylpiperazin
(Figure 1.5), a highly selective si
toxic effects such as convulsions, locomotor stimulatory activity and expression of sensitization 
[54, 154].  
 
The literature also shows compounds that have agonist actions at sigma receptors. These 
compounds such as BD1031 and DTG were successful in aggravating the acute locomotor 
stimulant effects of cocaine in mice 
1.9.1 Targeting Sigma-1  
Cocaine has been shown to have 10
1.4) [149]. Because of this, the sigma
mitigating cocaine effects. This was also made possible due to the cloning of the sigma
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receptor [79, 93, 96]. Using this data, synthesis of antisense ON targeting the mRNA of sigma-1 
receptors was carried out.  Subsequently, these ON led to a 40% reduction in the number of 
sigma-1 receptors in the brain by interfering with their synthesis [145]. Subsequently, it was 
observed that this decrease in brain sigma-1 receptors caused significant attenuation in cocaine-
induced convulsions, locomotor stimulant activity and conditioned place preference [145, 147, 
156]. This data was substantiated by conducting the same study using sense and mismatch ON as 
additional controls which resulted in no effect on cocaine-induced toxic effects thus concluding 
the reduction in these effects as a direct consequence of decrease in brain sigma-1 receptors [145, 
147]. One major drawback of this study was the intracerebroventricular route of administration 
that had to be used because of the poor permeation of ON across the blood brain barrier (BBB). 
Despite ON showing potential in attenuating the cocaine-induced toxic effects, therapeutically, 
this was not a feasible option. 
Table 1.4 Affinity of cocaine for sigma receptors [2] 
Drug Radioligand Tissue Sigma subtype Affinity Ki, 
nM 
Cocaine [3H](+)-
pentazocine 
Rat brain 
without 
cerebellum 
σ-1 2909 [145] 
Cocaine [3H]DTG + 
(+)-pentazocine 
Rat brain 
without 
cerebellum 
σ-2 29,175[145] 
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Improvising on what ON had to offer, candidates capable of crossing the BBB were examined 
using selective sigma-1 ligands. A behavioral study using BMY14802 [150] and rimcazole were 
compared against effects of a non-sigma agent, clozapine and a classical sigma receptor 
antagonist haloperidol and (+)-3-PPP [157]. 
All these historic ligands exhibited the ability to reduce cocaine-induced convulsions but it 
wasn’t clear if this was a result of their binding to sigma receptors since they exhibit an affinity 
to other sitesas well [146]. BMY14802 had a significant affinity for 5-HT1A and it was unclear 
if this affinity played a role in preventing the development of the cocaine-induced sensitization. 
Dextromethorphan (DXM) was among other candidates that were examined as a target for 
sigma-1. Despite its moderate sigma-1 receptor affinity (Ki = 419 nM), it was reported to prevent 
cocaine-induced behavioral effects [68-69, 158-159]. Dextromethorphan was found to have 
higher affinity for the NMDA receptors. These receptors are considered to play a role in the 
attenuation of cocaine-related effects. Analogs of DXM were synthesized with enhanced 
selectivity for sigma-1 receptors over phencyclidine (PCP) binding sites. None of these DXM 
analogs possessed good affinity for binding to sigma-2 receptors. Although these compounds 
could protect against cocaine-induced convulsions at higher doses, the lack of data correlating 
their anti-convulsant potencies to their affinities for sigma-1 receptors gave rise to speculations 
regarding involvement of other receptor mechanisms or an associated pharmacokinetic issue 
[160-162].  
Aside from the antagonist activity associated with antisense ON and sigma-1 antagonists, certain 
sigma-1 receptor agonists exhibited potential in enhancing cocaine-induced convulsions, 
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locomotor stimulant activity and other effects thus establishing the role of sigma-1 receptors in 
cocaine related toxic effects and addiction [145-146]. 
1.9.2 Targeting Sigma-2  
Cocaine has been known to have affinity not just for sigma-1 but also sigma-2 receptors. It is 
believed to cause the inhibition of NMDA-stimulated dopamine release from key areas of the 
brain. Research related to the discovery of antagonists for sigma-2 receptors is not as extensive 
as that for sigma-1. The literature does show some examples of sigma-2 antagonists with the 
ability to attenuate cocaine-related effects [163-164]. Ibogaine, an indole alkaloid obtained from 
the root of the African shrub Tabernantheiboga and its analogs displayed preferential sigma-2 
receptor affinity over sigma-1 subtype [124]. However, it was observed that ibogaine and its 
analogs have interactions with other receptors as well, hence was considered unsuitable for in 
vivo studies [124, 165]. Lu28-179 or Siramesine (1’-[4-[1-(4-fluorophenyl) – 1H-indol-3-yl] 
butan-1-yl] spiro [isobenzofuran-1(3H), 4’-piperidine], a piperidine analog was identified as a 
sigma-2 antagonist with preferential affinity for sigma-2 receptor (Ki = 0.12nM) [166-167]. It 
was believed to have a 140-fold affinity for sigma-2 over the sigma-1 subtype. Additionally, 
Siramesine also exhibited low affinities for dopaminergic D2, α-adrenergic, 5-HT1A and 5-HT2A 
receptors [167]. CB-184, a benzylidenephenylmorphan was one of the first sigma-2 ligands to be 
tested for its selectivity for the sigma class. This sigma-2 agonist had a 555 fold affinity for 
sigma-2 over sigma-1 receptors [123] but also had agonist activity with mu (µ)-opioid receptors 
[131-132, 138]. A series of (E)-8-benzylidene derivatives of 2-methyl-5-(3-hydroxyphenyl) 
morphans were synthesized which had preferential sigma-2 receptor affinity over sigma-1 in the 
range of 32-238 fold. These compounds also retained their potent in vivo affinity for µ-opioid 
receptors [122].  
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A series of 1, 4-dibenzylpiperazine compounds seemed to have anticonvulsant effects in mice 
administered with cocaine at 60mg/kg intraperitoneally[168]. Their in vivo potency had no 
correlation with the sigma-1 receptor affinity and selectivity. These findings further corroborated 
the role of sigma-2 receptors in attenuation of cocaine-induced convulsions. 
S14905, a selective sigma-2 compound was found to attenuate cocaine-induced locomotor 
stimulant activity in mice but had an affinity for other receptors as well [169].  In 2007, 
Matsumoto et al. identified two compounds, UMB24 and (±)-SM 21 with a high preferential 
affinity for sigma-2 receptors over the sigma-1 subtype [154].Behavioral studies conducted using 
these two compounds in mice resulted in significant attenuation of cocaine-induced convulsions 
and locomotor activity but had no influence on the lethality. This inability on the part of these 
two compounds may be due to fewer of sigma-2 receptors compared to sigma-1 in peripheral 
organs such as heart. It has been hypothesized that antagonists with mixed preferential affinity 
for sigma-1 and sigma-2 receptors may have better potential in mitigating cocaine-related 
convulsions than highly selective antagonists [154]. Also, the high dopamine (D2) affinity of 
UMB24 has been perceived to be the cause for locomotor depressant action in mice. 
Recently, Dr. Christopher R. McCurdy’s group from the Department of Medicinal Chemistry at 
the University of Mississippi synthesized a compound that is a derivative of 2(3H)-
benzothiazolone with 11 fold preferential subnanomolar affinity for sigma-2 receptors over 
sigma-1 [170]. However, it still has affinity for sigma-1 receptors. 
These compounds have established the critical role of sigma receptors in alleviating cocaine-
induced convulsions and locomotor stimulant activity; however more understanding is required 
to develop a medication for cocaine abuse and toxicity. Because of the lack of data regarding 
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structural information, amino acid sequence, the pharmacological characterization of sigma-2 
subtype and the absence of a truly selective sigma-2 ligands, the scope of research done in this 
area so far is very limited. Pharmacological studies show that sigma-2 receptors may be lipid raft 
proteins that affect calcium signaling via sphingolipid products [89, 131, 171]. It is difficult to 
ignore sigma-2 receptors because evidence suggests their involvement in the attenuation of 
cocaine-induced convulsions although their role in doing so is unclear [154]. The above-
mentioned compounds exhibit some ability in mitigating cocaine-related toxic effects in spite of 
their mixed receptor activity. Since cocaine has affinity to more than one target site, 
interpretation of any behavioral data can become challenging. Therefore, it is only reasonable to 
develop a pharmacological antagonist that is capable of crossing the blood brain barrier while 
having great preference for sigma-2 over sigma-1 receptors in addition to having high selectivity 
over other receptors and transporter systems in the brain. This will help delineate the exact role 
of sigma-2 receptors in cocaine abuse. A truly selective sigma-2 ligand will also aid in 
unmasking the protein sequence of the sigma-2 receptor thereby shedding light on its mechanism 
of action and biochemical role in various physiological effects. 
1.10 SN79 
In search of a selective sigma-2 ligand, Dr. Christopher R. McCurdy’s group from the 
Department of Medicinal Chemistry at the University of Mississippi synthesized a series of 
2(3H)-Benzoxazolone and 2(3H)-Benzothiazolone derivatives by varying the linker length from 
two to six carbons [170]. This was achieved by simple N-alkylation of 2(3H)-Benzoxazolone and 
2(3H)-Benzothiazolone with various dibromoalkanes and 4-cyclohexylpiperazine to produce the 
final analogs. These analogs were then converted to hydrochloride salts and tested in in vitro 
competition binding assays for sigma-1 and sigma-2 receptors from rat brain homogenates. 
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[3H](+)-Pentazocine was used to label sigma-1 receptors. [3H]DTG was used for sigma-2 
receptors in the presence of a blocking concentration of (+)-pentazocine. Non-specific binding 
was determined using haloperidol. It was found that these scaffolds had high affinity in the range 
of 2-10 nM for both the subtypes [170]. 
It was noted that compound CM121 with a four-carbon linker had a six-fold preference for the 
sigma-2 subtype over the sigma-1 subtype. Compounds with 2, 3, 5 and 6 carbon linkers 
exhibited similar affinities for both sigma-1 and sigma-2 receptors [2].  
Similarly, among the 2(3H)-Benzothiazolone derivatives synthesized, the four-methylene linker 
compound, CM145, exhibited an 11-fold selectivity with a subnanomolar affinity for sigma-2 
receptors.  Upon conducting further studies, it was hypothesized that presence of a four-carbon 
linker, 6-keto functionality in 2(3H)-benzoxazoloneheterocycle may be significant for sigma-2 
receptor affinity and selectivity [2]. From a set of compounds previously synthesized by Dr. 
Christopher R. McCurdy’s group from the Department of Medicinal Chemistry at the University 
of Mississippi, compound CM170 had 11-fold preference or sigma-2 receptor while compound 
CM142 had 7-fold selectivity for sigma-2 receptors.  
The presence of a 1-(4-fluorophenyl) piperazine moiety in CM170 and a 6-acetyl group in 
CM142 was considered significant for enhancement of sigma-2 receptor affinity and selectivity. 
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Based on these observations, the following features were deemed salient to design SN79 (Figure 
1.6) a putative selective sigma-2 receptor ligand:  
• Presence of a four methylene linker between two hydrophobic regions 
• Presence of a 6-acetyl group in the 2(3H)-benzoxazoloneheterocycle 
• Presence of a 1-(4-fluorophenyl) group at the piperazine ring 
  
 
Based on radio-ligand binding assays, compound SN79 exhibited high affinity for sigma-2 
receptors (Ki = 6.89±0.09 nM) with partial affinity for sigma-1 receptors (Ki = 28.03±3.39 nM) 
[172]. 
1.10.1 Pharmacological evaluation of SN79 in rodents 
Researchers in Dr. Rae R. Matsumoto’s lab from the Department of Basic Pharmaceutical 
Sciences at West Virginia University studied the antagonist effect of SN79 on cocaine actions in 
male Swiss Webster mice [172]. When pre-treated with SN79 (0.1-10 mg/kg) i.p. followed by 
convulsive dose of cocaine administered after 15 min, percentage of mice with convulsions 
decreased in a dose dependent manner [172]. According to previously conducted studies, sigma 
Figure 1.6 Structure of SN79 
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receptor agonist as well as antagonists and 5-HT2 antagonists tend to have anticonvulsant effects 
thereby mitigating cocaine-induced convulsions [173-174]. Pre-treatment with SN79 given orally 
followed by a convulsive dose of cocaine (80 mg/kg) also had a significant effect on percentage 
of mice exhibiting convulsions, causing a decrease from 78 to 20% [172]. SN79 was reported to 
have caused a dose dependent decrease in cocaine-induced hyperactivity having some sedative 
effect of its own [172]. Apart from the above mentioned observations, SN79 also inhibited 
development of cocaine-related sensitization [172], an attribute previously associated with 5-HT2 
antagonists [175]. Studies conducted by Dr. Matsumoto’s researchers reinforce the role of sigma 
receptors in mitigating cocaine-induced effects [172].  
SN79 caused no inhibition of some major cytochrome P450 enzymes such as CYP1A2, 
CYP2A6, CYP2C19, CYP2C9*1, CYP2D6 and CYP34A [172] thereby eliminating the 
possibility of any drug-drug interactions in vivo [172].  
Based on these results, SN79 can be categorized as a potential pharmacotherapy to mitigate acute 
as well as subchronic effects of cocaine thereby making it necessary to study critical ADME 
properties of this compound. 
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CHAPTER II: IMPORTANCE OF PHARMACOKINETICS IN DRUG DISCOVERY 
AND DEVELOPMENT 
2.1 Role of Pharmacokinetics and Metabolism in Drug Discovery and Development 
Drug discovery and development encompass the functional process of searching for new drugs. 
The discovery stage is characterized by identifying the target enzyme/receptor for a particular 
disease establishing surrogate markers (or suitable models) for biological activities, and testing 
the new drug candidates for in vitro and/or in vivo biological activities [176]. The development 
stage consists of evaluation of the toxicity and efficacy of the new drug molecules. In the United 
States, the average time taken for a new chemical entity to enter the market involves 10-15 years 
of research at a cost of almost a billion dollars [176]. Compounds that fail in preclinical or 
clinical studies largely affect the drug discovery process and also gives rise to obvious time and 
cost penalties. 
Lead compound optimization is achieved through the screening of a multitude of compounds 
based on desired target affinity. These results aid medicinal chemists in modifying the structure 
of the compound based on a variety of empirical and semi-empirical structure activity 
relationships to amplify its in vitro activity. Along with in vitro studies, supporting in vivo data is 
required to understand whether or not the compound of interest has good bioavailability and 
duration of action. When a new chemical entity (NCE) is discovered, it is important to 
understand its therapeutic activity in the body and achieving ways to optimize its potency. 
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Information pertaining to its biological, physical and physicochemical properties will help design 
a drug delivery system that enhances in vivo targeting efficacy. It is not easy to fully determine 
the pharmacokinetics of a drug in vitro, therefore early preclinical pharmacokinetics is a rational 
approach to address this issue. In this stage, certain characteristics are measured that help decide 
whether or not the NCE is a potential drug candidate. This data guides us to better understand if 
the compound of interest after administration, acts and remains at the targeted site producing a 
concentration-time profile to elicit the desired response. These studies help reduce attrition rate 
at the in vivo and clinical phases. For this reason, pharmacokinetics and metabolism play 
instrumental roles not just in drug development phase but should also be employed in discovery 
stage as determinants of in vivo drug action.  
The experimental design of studies and selection of animal species play a vital role in providing 
crucial data that help predict drug absorption and elimination in humans. Any errors in the 
consideration of these two parameters can cost the researchers loss of a good compound. 
Regulatory agencies require a thorough understanding of the pharmacokinetics and metabolic 
processes of a new drug. Many psychotropic drugs have shown tendency to form metabolites 
with their own biological activity [177]. This kind of behavior offers an explanation in cases of 
toxicity for some drugs. Before studying metabolism in humans, in vitro studies are done to 
establish the compound’s metabolic half-life. During the drug development stage, it is desirable 
to identify the enzymes responsible for drug metabolism in humans. This data can prove useful 
in designing clinical studies, specifically those involving drug-drug interactions. Comparison of 
metabolism in humans and animals is important in the early stage of drug development to aid in 
selection of appropriate animal species for toxicity studies. Latest technologies such as LC-MS, 
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high-field NMR and LC-NMR techniques aid in obtaining early information on the metabolic 
pathways of new drug candidates in the drug development phase. 
The literature contains references to many compounds discovered serendipitously – the 
antituberculosis agent, isoniazid [178-179], anxiolytics such as diazepam and chlordiazepoxide 
[177, 180-181]. Through a better understanding of disease pathways and recent advances in 
molecular biology and protein chemistry, mechanism-based drug design became feasible. This 
helps interrupt specific biochemical processes by targeting certain types of enzymes and/or 
receptors. Computer-aided graphics has also introduced structure-based design. These 
approaches have been successfully employed to maximize drug activity within certain structural 
limits. However, good in vitro activity does not necessarily warrant good in vivo activity in case 
of specific drugs. This may be a consequence of undesirable pharmacokinetic parameters, and 
toxicity resulting from metabolites with biological activity of their own. Pharmacologically, the 
metabolite may behave similarly as the parent compound, via different mechanisms or even 
antagonism. Therefore, incorporating pharmacokinetic and metabolism data with biochemical 
and pharmacological data characterize an optimal drug design.  
2.1.1 Pharmacokinetics and Drug Design 
Many drug candidates are discarded because of their weak pharmacokinetic properties, such as 
too long or too short half-life, undesirable absorption, and extensive hepatic first-pass 
metabolism. The high rate of attrition of new drug candidates as a result of to their serious 
pharmacokinetic problems indicate that the significance of pharmacokinetics in the drug 
discovery and development process.  Two important parameters that define good 
pharmacokinetics properties are good bioavailability and a desirable half-life. Therefore, through 
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suitable chemical modifications to the drug design, it is possible to attain drug candidates with 
optimum pharmacokinetics. The following factors help define drug absorption and disposition. 
2.1.1.1 Absorption 
Absorption of a drug is largely dependent on physicochemical and biological factors. Two 
important physicochemical properties influencing drug absorption are lipophilicity and solubility 
[182] (Figure 2.1). The oral bioavailability of a drug is characterized by the amount of oral drug 
dose that reaches systemic circulation.  
 
 
 
 
 
Figure 2.1 The two important rate determining steps (RDS) for absorption of drugs from 
oral administration [183]. 
Drugs entering the body via oral route encounter the membrane of gastrointestinal tract made of 
phospholipids interspersed with proteins. The rate and extent of transcellular passage of drugs 
across this lipid bilayer is determined by the lipophilicity of the drugs. In case of barbiturates, it 
has been observed that increasing lipophilicity causes increased membrane permeability thereby 
exemplifying the correlation between lipophilicity and increased permeability [184]. Drug 
absorption from the gastrointestinal tract is also defined by the susceptibility of the drug to 
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metabolize in the liver. Before the drug reaches systemic circulation, blood supply of the upper 
gastrointestinal tract passes through the liver thereby exposing the drug to first-pass effect. A 
drug with high metabolic clearance is extensively metabolized by the liver and gut wall during 
first passage of absorption, hence resulting in low bioavailability. From studies conducted by 
Seydel et al., it has been understood that the lipophilicity of a drug is directly proportional to 
membrane permeability and first–pass metabolism [185-186]. Therefore, optimization of 
lipophilicity is crucial in maximizing membrane permeability and minimizing first-pass 
metabolism to enhance bioavailability.  
Solubility also plays a significant role in ascertaining drug absorption into systemic circulation. 
Drugs with poor aqueous solubility pose a hindrance to absorption. By applying modifications to 
drug design, solubility can be altered to make the drugs suitable for oral delivery. One such 
approach is using the salt form of the drug instead of the free base. Merck research laboratories 
designed a HIV protease inhibitor called indinavir sulfate [187-188]. It was found to be a better 
oral dosing agent as against its free base indinavir. The free base suffered from high lipophilicity 
and low aqueous solubility (0.07 mg/mL at pH-7.4), thereby limiting its absorption. The salt 
form had enhanced solubility (60 mg/mL at pH-3.5) adverse to the indinavir free base, 
facilitating its aqueous solubility, subsequently enhancing drug absorption in acidic pH of the 
gastrointestinal tract [187-188]. Apart from structural modifications, formulation optimization 
also helps augment drug absorption [189]. 
2.1.1.2 Distribution 
Distribution of the drug in the body plays a vital role as one of the determinants of 
bioavailability. Distribution is also characterized by the lipophilicity of the drug. Highly 
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lipophilic drugs exhibit high protein binding, thereby displaying a high distribution level [185-
186]. A study conducted on 15 basic drugs in dogs exemplified the effect of increased 
lipophilicity on enhancing volume of distribution [190]. Aside from lipophilicity, the extent of 
the drug binding to plasma and tissue proteins also governs drug absorption in adipose tissues 
[191]. Delivery to brain has several limiting factors in comparison to other organs in the body. 
The presence of a highly lipophilic barrier, known as blood-brain-barrier (BBB), necessitates 
perfusion of drugs into the brain via simple diffusion.  For drugs whose activity is warranted in 
the central nervous system (CNS), it is important to understand the functioning of the BBB in 
order to gain access to the site of action. Most drugs crossing the BBB do so by passive 
diffusion, thereby establishing the significant role of lipophilicity in brain penetration. Recent 
studies indicate that an octanol/buffer partition coefficient (log P) value between 1 and 2 is 
deemed optimum for CNS drugs [192](Figure 2.2).  
 
Figure 2.2 Graph showing correlation between distribution and lipophilicity of 257 
marketed drugs [192]. 
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Contrary to popular beliefs that increase in lipophilicity causes enhanced brain permeation, it has 
been reported that a linear relationship between lipophilicity and brain permeation occurs only 
within a certain range. Inhibition of P-glycoprotein has also shown enhancement in BBB 
permeation of some highly lipophilic drugs [193-194]. 
2.1.1.3 Drug Half-life 
The biological half-life of a drug is a crucial determinant of the dosage regimen. It is defined as 
the time taken for the amount of drug in the body as well as plasma concentration to decline by 
one-half or 50% its initial value. The half-life of a drug reflects the duration of drug action. In 
order to obtain therapeutically significant drug levels in plasma, fixed dosing is given at regular 
time periods. A drug with shorter half-life postulates frequent dosing thereby affecting patient 
compliance. Today, half-life is considered a secondary parameter that is defined by primary 
parameters - clearance and apparent volume of distribution. In order to attain desired 
pharmacokinetics, a drug with prolonged half-life is reckoned as ideal.  Two approaches to 
prolong drug half-life and reduce dosing frequency are by increasing the volume of distribution 
or decreasing elimination clearance. Chemical modifications made to the structure seem to offer 
the requisite plasma half-life in certain drugs. An example of this is nifedipine, a calcium 
channel blocker used to treat hypertension.  With its limitations such as short plasma half-life (~2 
hours), high dosing frequency and substantial first-pass effect [195], investigators were tasked 
with developing a drug with improved bioavailability and prolonged half-life. Structural 
modifications led to the development of amlodipine, which is also a 1, 4-dihydropyridine 
derivative, similar to nifedipine that exhibits antihypertensive activity. This compound when 
examined in clinical studies displayed good oral bioavailability (50-60%) and increased plasma 
half-life (~30 hours) [196-197]. Another strategy to prolong half-life is formulation modification. 
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A sustained-release drug delivery system or co-administration of inhibitors of drug-metabolizing 
enzymes has been shown to have an escalating effect on plasma half-life [198].  
2.1.1.4 Stereoisomers 
Many marketed pharmaceutical drugs contain racemic mixtures without much knowledge about 
the pharmacokinetic data for each individual stereoisomer. It is imperative to understand the role 
of stereochemistry in drug development because stereosiomers of a chiral drug are known to 
exhibit marked differences in their pharmacokinetic and pharmacodynamic behavior [176]. It is 
common for one stereoisomer to exhibit desirable bioavailability and plasma half-life over the 
other stereoisomer of a chiral drug. Careful perusal of the similarities/dissimilarities between the 
activities of (+) and (-) isomers is necessary to identify the most optimal enantiomer for drug 
development. For specific drugs, the use of a racemic mixture resulted in better therapeutic 
profile than with a single enantiomer. Indacrinone, a drug used for its uricosuric and diuretic 
activities, is marketed as a 9:1 racemic mixture of the (+) - and (-)-isomers [199-200]. Specificity 
of receptors is also a determinant in selection of isomers. β1-adrenergic receptors have better 
affinity than β2 subtype to timolol, a nonselective β-adrenergic antagonist due to the presence of 
a chiral center in the amino-hydroxypropoxy side-chain [201]. 
The examples mentioned in this topic exemplify the role of pharmacokinetics in guiding drug 
disovery and development.  
2.1.2 Metabolism and Drug Toxicity 
Regulatory agencies warrant extensive toxicity studies to be conducted in laboratory animals 
before proceeding to clinical studies. Despite exploring safety in animals, extrapolating toxicity 
assessments from animals to humans can be challenging. Drug-induced toxicity is species-
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dependent due to the tendency of certain laboratory animals to exhibit typical mechanisms of 
developing toxicity that extrapolation of such data to humans would be incorrect [202-205]. In 
order to accurately interpret this behavior, it is necessary to understand the various metabolic 
pathways and other mechanisms influencing species variation in metabolism and 
pharmacokinetics. 
2.1.2.1 Species Induced Differences in Metabolism 
Most of the mammals, despite descending from a common ancestor have evolved into different 
beings by adapting to their environment. There are many variations with respect to amino acid 
sequences in species. Considering one of the most instructive cytochromes, P-450, biochemists 
have been able to isolate at least 14 P-450 families to date [206]. Though P-450 was perceived to 
have evolved from a single ancestral gene, there are significant differences in the amino acid 
sequences across species [207]. Changes in amino acid sequence invariably influence substrate 
specificity [208]. This has a profound effect on both rate of drug metabolism and the metabolite 
pattern between animal species. Species differences have been observed by both phase I and 
phase II reactions. In phase I reactions, both quantitative and qualitative differences in the 
enzyme and its activity have been reported. On the other hand, phase II reactions only illustrated 
qualitative differences. Drugs undergo metabolism in a number of pathways depending on the 
species. The metabolism of Indinavir, a potent HIV protease inhibitor, yielded different values of 
intrinsic clearance in animals and humans [209]. In humans, indinavir was metabolized through a 
number of pathways – (a) glucoronidation at the pyridine nitrogen yielding a quarternized 
ammonium conjugate, (b) pyridine N-oxidation, (c) para-hydroxylation of the phenylmethyl 
group, (d) 3’-hydroxylation of the indan, and (e) N-depyridomethylation[209]. It was observed 
that indinavir produced oxidative metabolites in humans and animals, while N-glucoronide was 
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formed only in human and monkey urine [210]. The intrinsic clearance (cLint)(Vmax/Km) values 
of indinavir was in the following order: rat (157 mL/min/kg) ≈ monkey (162 mL/min/kg) > dog 
(29 mL/min/kg) > human (17 mL/min/kg) [210]. These values exemplify the quantitative and 
qualitative variations in metabolism of indinavir across different species. Induction is another 
mechanism that influences metabolism. In a study conducted by Conney et al [211], animals 
treated with 3-methyl-cholanthrene displayed enhanced ability in metabolizing 
methylatedaminoazo dyes. Omeprazole, a gastric-acid suppressant, acts as a CYP1A2 inducer in 
humans but not in mice or rabbits [212-213]. Induction of drug-metabolizing enzymes may or 
may not increase toxicity depending on the balance between detoxification and metabolite 
activation. Aside from species variation, difference in sex is also an important determinant of 
toxicity. According to recent studies, sexual dimorphism in laboratory animals is largely 
attributed to the differential expression of sex-dependent cytochrome P-450s [214-216]. Hepatic 
cytochrome P-450 is responsible for metabolic inactivation and/or activation of a drug. Any 
differences in the levels of P-450 expression due to sex affect the toxicological response as it 
affects the susceptibility of the tissue to drug-exposure. Thus, regulatory agencies warrant safety 
assessment data in equal number of males and females of each species.  
The onset of toxicity is not always an attribute of the parent drug, but can also arise due to the 
formation of reactive toxic metabolites for certain drugs. Studies indicated that acetaminophen, 
commonly used for its antipyretic and analgesic activities, tends to induce hepatotoxicity in mice 
at doses ~ 200-300 mg/kg while in rats (doses >1500mg/kg), barely detectable hepatotoxicity 
was observed. These results suggest that the amount of reactive metabolite formed varies from 
species to species; sometimes completely absent in one particular species. Thus, monitoring the 
parent drug alone in vivo has very little relevance.  
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2.1.2.2 Stereoselectivity and Toxicity 
Safety assessments also extend to studying stereochemistry of parent compound. 
Pharmacokinetic and pharmacodynamic differences of enantiomers are a consequence of their 
varied interactions with biological macromolecules [217-220]. Steroselective plasma protein 
binding is a species-dependent phenomenon. Also, stereoselective metabolism has been 
documented in case of certain drugs. In vitro metabolism of Mephenytoinenantiomers was 
studied in different species and humans [221]. R-mephenytoin underwent microsomal 4’-
hydroxylation 2 to 6 times higher thansS-mephenytoin in rabbits, dogs and rats whereas the rates 
were 5 to 15 times higher with S-enantiomer than R-mephenytoin in monkey and humans. These 
results manifest the significance of species selection and help decide whether to develop a 
racemate mixture or individual enantiomer while conducting safety assessments in laboratory 
animals before the data are extrapolated to humans.  
2.2 Kinetics of Cocaine distribution and elimination 
The measurement of cocaine and its metabolites has considerable relevance to cocaine research, 
both clinical and basic, and to that controversial and fuzzy interface between medicine and social 
policy defined as drug abuse screening [222]. Cocaine hydrochloride, a crystalline salt, is 
commonly inhaled or injected. Cocaine is a tertiary amine with pKa of 8.6. It is a weak base and 
crosses cell membranes quickly and efficiently [223]. At higher pH values, the un-ionized or 
freebase form predominates while at a more acidic pH, cocaine exists in the salt form. 
Traditionally, the free base was prepared by alkalinizing an aqueous solution of the salt form and 
extracting the freebase using an organic solvent such as ether that was then evaporated. The route 
of administration largely influences the rate and bioavailability of cocaine entering systemic. 
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Figure 2.3 illustrates the differences in peak plasma levels of cocaine when approximately 
equipotent doses were administered to the same ten subjects via various routes [223]. When 
cocaine was administered intranasally in surgical parents for vasoconstriction and local 
anesthesia prior to intubation, peak plasma levels were detected in blood one hour after 
administration [224]. Vasoconstriction limits the rate of absorption and thus variable amounts are 
swallowed. When inhaled, absorption from nasal mucosa was found to be similar to absorption 
from mouth and the gastrointestinal tract after oral administration and much slower than after 
smoking or after intravenous administration [225-226]. After inhalation or oral administration, 
peak plasma levels were found after 60 minutes although great variability between individuals 
exists ranging between 30 to 120 minutes [223]. Oral and nasal bioavailability has been found to 
be 30 to 40 percent with the remainder eliminated by first-pass metabolism [223]. Depending on 
the route of administration, Cocaine doses commonly range from 0.2 to 3 or 4 mg/kg. The rate of 
injection during intravenous administration is an important determinant of peak cocaine levels in 
the systemic circulation. Peak plasma levels can range from 50 to 2000 ng/mL depending on 
route and rate of injection.  
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Figure 2.3 Plasma levels of cocaine when dosed via various routes. [223]. 
Cocaine, once administered, is found to be widely distributed through body tissues with a 
volume of distribution ranging from 1.5-2 L/kg [225, 227]. Its volume of distribution is small 
compared to some psychotropic drugs such as methadone (3.6-6.7 L/kg) [228-229], desipramine 
(20 L/kg) [230] and naltrexone (15 L/kg) [231]. Cocaine is found in low concentrations in body 
fluids and is known to exhibit very rapid metabolic disposition. Also, cocaine is susceptible to 
enzymatic and spontaneous hydrolysis both in vitro and in vivo; for the afore-mentioned reasons, 
accurate measurement of cocaine represents an interesting challenge to researchers [222]. When 
cocaine incubated with human plasma or with liver homogenates, it rapidly hydrolyzes to form 
an ecgonine methyl ester, which is one of cocaine’s two major metabolites [232-235]. About 1 to 
5 percent of an administered dose of cocaine is excreted unchanged in urine [223]. About 75 to 
90 percent is eliminated as inactive metabolites such as the ecgonine methyl ester and 
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benzoylecgonine[224, 236-238]. An N-demethylation of cocaine in hepatic microsomes 
produces norcocaine, the only pharmacologically active metabolite of cocaine [239]. Cocaine is 
rapidly eliminated from the body with an elimination half-life of about 1 hour and total body 
clearance of about two liters per minute [240-242]. The elimination half lives of cocaine’s 
metabolites, benzoylecgonine and ecgonine methyl ester are 6-8 hours and 3-8 hours respectively 
[223]. 
There is continuing controversy over using a one-compartment or two-compartment system for 
studying the distribution of intravenous cocaine. In 1977, Kogan et al. [243] reported for the first 
time that cocaine plasma concentrations declined multi-exponentially when dosed at 100 mg 
intravenously with half-lives of 20-40 min for a distribution phase and 2.8 h for the terminal 
phase. This data was found to be best fit by a two compartment model [242]. On the contrary, 
Javaid et al. [244] found the distribution of intravenous cocaine to decline mono-exponentially at 
a dose of 32 mg. Barnett et al. [240] studied the distribution of cocaine in two subjects using a 
200 mg dose and found that the plasma levels were best described by a bi-exponential function in 
one subject and by a mono-exponential function in the other. Chow et al. studied the 
pharmacokinetics of cocaine in five healthy subjects at a low dose of 32 mg [241]. The 
concentration data was modeled using a two compartment system and the authors speculate that 
the very rapid distribution phase of cocaine was not taken in account in the earlier studies 
because sampling was not done early enough after drug administration [241]. Cocaine dosed at 
100 mg to three patients resulted in concentration data following mono-exponential function. 
This prompted Barnett et al. and other investigators to conclude that the disposition of cocaine in 
the human body has pronounced dose dependence over the dose range studied [244]. Many 
pharmacokinetic parameters are dose-defined over the range of 1.1 – 2.9 mg/kg. The resolution 
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of the dose-dependent disposition of cocaine relies on further investigations such as 
measurements of both drug and metabolites in plasma, urine and consideration of an extended 
dose range. 
2.3 Pharmacokinetics of Sigma Receptor Antagonists 
Early reports on opioid-induced behavioral and psychotomimetic effects were originally thought 
to be produced by sigma receptors [81]. Many typical and atypical antipsychotic drugs, including 
haloperidol, bind with high affinity to the sigma binding site leading to the hypothesis that a 
sigma ligand may be an effective therapeutic solution for a new class of antipsychotic drugs 
without the serious motor side effects of traditional neuroleptic agents. This approach has led to 
the identification of several new antipsychotic agents in animal behavioral studies with binding 
affinity to sigma receptors [157]. The preclinical behavioral effects of DuP 734 indicate its 
potential as an antipsychotic agent without the extrapyramidal symptoms of neuroleptics[245]. 
DuP 734 exhibits high affinity for both sigma (Ki= 10 nM) and 5-HT2 receptors (Ki= 15 nM), 
weak affinity at D2 and PCP receptors (Ki> 1.0 µM) and no appreciable affinity for any other 
receptor, ion channel or second messenger system in vitro[246]. Kapil et al. investigated the 
pharmacokinetics of DuP 734 [247] in mice, rats, beagle dogs and cynomolgus monkeys at 
different intravenous and oral doses. Mice were given an IV bolus dose of 3.1 or 8.0 mg/kg and 
p.o. dose of 3.1, 11.2 or 31.1 mg/kg. Rats were given an IV bolus injection of 3.7 mg/kg and p.o. 
dose of 12.5, 25 and 50 mg/kg. Beagle dogs were given a single IV bolus dose of 1 or 3 mg/kg 
and oral dose of 1, 3 and5 mg/kg. Cynomolgus monkeys received single IV bolus injection of 
0.77 mg/kg and p.o. dose of 9.3 mg/kg respectively [247]. The distribution of DuP 734 in plasma 
was characterized by high total body systemic clearance ranging between 46 to 87 mL/min/kg 
and large steady state volume of distribution (3.6 to 6.8 L/kg). The terminal elimination half-life 
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was in the range of 50 to 83 min. DuP 734 was found to have extensive distribution in all 
species, a desirable pharmacokinetic property for a compound that acts on the central nervous 
system. This compound exhibited rapid gastrointestinal absorption from an aqueous solution in 
mice and rats with peak plasma concentrations achieved within 5 and 20 min following 
administration. The peak plasma concentrations were attained within 45 and 130 min in dogs and 
monkeys. DuP 734 was also found to have a high systemic clearance, indicating that it will be 
susceptible to hepatic first pass elimination upon oral dosing. This assumption was based on the 
understanding that the blood to plasma distribution ratio of DuP 734 approximates unity. Studies 
conducted by infusing DuP 734 directly into the portal vein of rats [248] reported that 
approximately 94.5% of drug delivered to the liver via portal route was eliminated and only 
6.5% reached the systemic circulation. This may be the underlying cause for low oral 
bioavailability of DuP 734 in all the species. Low bioavailability at lower doses in mice, rat, dog 
and monkeys was observed which could be attributed to one of more processes including 
incomplete absorption from gastrointestinal tract, chemical degradation in the gastrointestinal 
tract, metabolism by the intestinal flora and/or gut wall and/or hepatic first-pass metabolism 
[247]. 
Dextromethorphan (DXM), a sigma receptor agonist and an NMDA receptor antagonist, has long 
been examined for its ability to attenuate acute opiate and ethanol withdrawal [68-69, 158-159].  
The interest in DXM relates to its CNS pharmacological properties including the binding to high 
and low affinity binding sites in the brain [160, 249-252]. There isn’t enough information on the 
pharmacological mechanism of DXM abuse in humans. However; several studies reported that 
its metabolite, dextrorphan, is responsible for its phencyclidine (PCP)-like behavioral effects 
[253-254]. When injected to rats at a dose of 30 mg/kg intraperitoneally (i.p.), the bioavailability 
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of DXM was 1.3 fold lower and the formation of dextrorphan and other metabolites was 3 fold 
greater as compared to the same dose given subcutaneously [255]. Wills et al. reported that in 
comparison to the IV route, the absolute bioavailability of DXM in the rat was 25% after i.p 
administration and 10% after p.o. administration [256]. These findings clearly indicate that DXM 
undergoes extensive hepatic first pass metabolism. In considering pharmacokinetic studies, it is 
therefore prudent to understand the effect of route of administration on disposition of the drug 
and its metabolites in addition to many other factors such as dosage and time of testing.  
2.4 Relevance of Pharmacokinetics and Metabolism in furthering of SN79 
In 1988, Sharkey et al. reported cocaine’s affinity to sigma receptors [80]. Based on the 
hypothesis that blocking sigma receptors can help attenuate cocaine related toxicity and 
addiction, researchers have focused their attention in developing highly selective sigma-1 and 
sigma-2 ligands. In this view, as mentioned in Section 1.10, SN79, preferring sigma-2 receptor 
antagonist was synthesized by Dr. Christopher R. McCurdy’s group from the Department of 
Medicinal Chemistry at the University of Mississippi. In comparison to the research conducted 
on sigma-1 subtype antagonists, work indicating involvement of sigma-2 receptors in cocaine-
induced effects are nominal. This is attributed to the fact that sigma-2 receptors have not yet 
been cloned and there are no antisense oligonucleotides to reduce their number. For reasons 
mentioned in Section 2.5, extensive pharmacokinetic and pharmcodynamic evaluation of SN79 
in laboratory animals will help define accurately the biological role of sigma-2 receptors in 
attenuating cocaine-induced toxicity and addiction before furthering into clinical studies.  
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CHAPTER III: BIOANALYTICAL METHOD DEVELOPMENT AND VALIDATION 
USING ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY-MASS 
SPECTROMETRY 
3.1 Introduction 
There is an emerging opportunity to surpass the rate of sample generation with the rate of sample 
analysis, considering the high number of compounds generated during the drug discovery stage. 
In order to narrow the timeframe for analysis, traditional analytical approaches need to be 
adjusted keeping in mind the advances in sample generation. Rapid, high throughput, sensitive 
and selective methods are warranted for pharmaceutical analysis [257]. Breakthrough advances 
have been made in analytical methods used to expedite the drug development process allowing 
for the detection of trace elements/metabolites at the nanogram and pictogram per liter range. A 
significant number of analytical methods based on liquid chromatography tandem mass 
spectrometry (UPLCTM) enable the detection of pharmaceutical compounds in different 
biological matrices such as plasma, serum, urine and feces [258]. LC/MS techniques are 
applicable to a wide range of pharmaceutical compounds and are characterized by powerful 
analytical figures of merit such as selectivity, sensitivity, speed of analysis and cost 
effectiveness. The idea that UPLC/MS is now frequently used in every stage of drug 
development exemplifies its acceptance. In view of the widened scope of applications that 
UPLC/MS technique offers in addition to the afore-mentioned figures of merit, we employed this 
tool for most of the analytical evaluations mentioned in this dissertation. 
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3.2 Bio-analytical Method Development and Validation 
The Food and Drug Administration (FDA) provides validation guidelines [259] to be followed 
for bio-analytical procedures such as gas chromatography (GC), high-pressure liquid 
chromatography (LC) and other hyphenated LC mass spectrometric procedures. Based on these 
recommendations, we developed a rapid, sensitive and selective UPLC/MS method for 
quantization of SN79 in rat plasma. 
3.3 Chemicals and reagents 
HPLC grade acetonitrile, methanol, chloroform, and water were from Fisher (Fair lawn, NJ, 
USA). Reagent grade trifluoroacetic acid was purchased from Sigma-Aldrich (95%, St. Louis, 
MO, USA). Drug-free rat plasma was bought from Innovative Research Inc. (Southfield, MI, 
USA). Rat liver microsomes were purchased from CellzDirect Inc. (Durham, NC, USA). Sodium 
chloride (0.9% w/v) was purchased from Abbott Laboratories (North Chicago, IL, USA). SN79 
and CM156 were supplied by Dr. Christopher R. McCurdy’s group from the Department of 
Medicinal Chemistry at the University of Mississippi. The purity of the compounds was proved 
to be over 98% by H1-NMR and C13-NMR. 
3.4 Liquid chromatography and Mass spectrometry 
3.4.1 SN79 
A Waters Acquity UPLC system was used (Milford, MA, USA). Chromatographic separations 
were performed on a Waters Acquity UPLCTM BEH C18 column (1.7 µm, 2.1 × 50 mm). 
Collision gas used in mass spectrophotometer was argon while nitrogen was used as desolvation 
and cone gas for mass spectrophotometer. The mobile phase consisted of acetonitrile: methanol 
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(95:5) and 0.3% trifluoroacetic acid (50:50, v/v). The flow rate was held at 0.2 mL/min, the 
sample injection volume was 10 µL, and the duration of the run was 2 min. 
The mass spectrometry equipment consisted of a Waters Micromass Quattro MicroTM triple-
quadrupole system (Manchester, UK). The mass spec system was controlled by version 4.0 Mass 
Lynx software. Ionization was performed in the positive electro spray mode. Mass spec 
conditions were the following: capillary voltage 4.69 kV, cone voltage 51V, extractor voltage 
4V, RF lens voltage 0.3V. The source and desolvation temperatures were maintained at 120°C 
and 450 °C, and the desolvation and cone gas flows were held at 380.2 and 95.8 L/hr, 
respectively. The selected mass-to-charge (m/z) ratio transition of SN79 [M+H] + used in the 
single ion reaction (SIR) was m/z: 412.3, respectively. The dwell time was set at 500 ms. The 
mass scan of SN79 is shown in Figure 3.1. 
 
Figure 3.1 Mass scan of SN79 
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Figure 3.2 Test for specificity 
Chromatogram of blank rat plasma 
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Figure 3.3 Chromatograms of SN79 and rat plasma spiked with SN79 
 
 
A- Blank plasma spiked with SN79. 
B- Blank plasma spiked with CM156 (internal standard). 
C- Plasma sample collected from rat 3 hours after oral administration of SN79 spiked with 
CM156. 
A 
B 
C 
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3.4.2 Internal Standard 
An internal standard in analytical chemistry is a chemical substance of known amount, different 
from the analyte, which is added to the unknown sample. The internal standard must provide a 
signal that is similar to the analyte signal but sufficiently different so that the two signals are 
readily distinguishable by the instrument. Peak area of the analyte is compared to peak area of 
the internal standard to calculate the amount of analyte as a function of the analyte standard 
concentration. This ratio is used to obtain analyte concentrations from a calibration curve.  
provides numerous advantages in liquid chromatography/tandem mass spectrometric 
bioanalytical techniques such as reduction of the analysis run time, improvement in the intra-
injection reproducibility, impact reduction of matrix and ionization effects [260]. Internal 
standards are particularly useful when you have considerable "sample clean-up" to do. Use of an 
IS will prevent sample to sample fluctuations in extraction efficiency from ruining your precision 
and accuracy. The internal standard acts as a carrier for low concentrations of the analyte such 
that it can determine the lower limit of detection for every sample. The addition of IS corrects for 
analyte losses during sample preparation [261].  
An external standard is similar to the internal standard (known behavior), but is not added to the 
unknown sample. It is run alone, as a sample, and usually at different concentrations, to generate 
a standard curve. Again, the peak areas are related to the known amounts of external standard 
run. Unlike internal standards, external standards do not correct for losses that may occur during 
preparation of the sample, such as extraction, centrifugation, evaporation, etc.  
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3.5 Method validation in Rat Plasma 
Bio-analytical method validation must be performed to ensure that the analytical procedures 
developed generate reproducible and reliable data in order to correctly interpret preclinical data 
such as bioavailability and bioequivalence from pharmacokinetic, pharmacology and toxicology 
studies. The validation process establishes the robustness of analytical methods when transferred 
between labs and/or analysts. Full validation is necessary for all new chemical entities. The 
validation of a UPLC/MS method includes linearity, selectivity, inter- and intra-assay precision 
and accuracy, stability, recovery and ion suppression studies. 
3.5.1 Standards preparation 
SN79-di-hydrochloride was used to prepare the standard solutions. To prepare a stock solution 
with a concentration of 1 mg/ml of SN79, 1.18 mg of SN79-di-hydrochloride was dissolved in 1 
mL of HPLC grade water. Further dilutions were made using HPLC grade water to get final 
concentrations of 50, 100, 150, 500, 1,000, 2,000, 5,000, 10,000, 30,000 and 50,000 ng/ml. 
CM156 (internal standard) was prepared at a concentration of 10 µg/ml in HPLC grade water. To 
prepare the standards, 80 µL of blank rat plasma was taken, to which 10 µL each of standard 
stock solution was added to get final concentrations of 5, 10, 15, 50, 100, 200, 500, 1,000, 3,000 
and 5000 ng/ml. To these standard solutions, 10 µL of the internal standard (10µg/ml) was added 
to get a final volume of 100 µL. Chloroform was used as the extraction solvent. Five hundred 
micro-liter of chloroform was added to these samples and the micro-centrifuge tubes were 
vortexed for 10 minutes on VWR Signature® pulsing vortex mixer (VWR Scientific Inc., U.S.A). 
The samples were centrifuged at 3000 rpm for 20 minutes using an Accuspin Micro 17R 
centrifuge (Fisher Scientific, U.S.A). The organic phase (400 µL) was transferred into 1.5 mL 
 eppendorf tubes (Fisher Scientific, U.S.A) and dried in a vacuum oven (Precision, Jouan. Inc, 
USA) at 25 oC. To the dried samples, 100 µL of mobile phase was added and vortex mixed for 2 
minutes. The mobile phase consisted of acetonitrile: methanol (95:5) and 0.3% trifluoroacetic 
acid (50:50, v/v). All the samples were filtered with a 0.2 µm syringe filter (Wate
0.2 µm) and analyzed using the UPLC/MS.
Quality Control (QC) samples were prepared separately at concentrations of 5, 15, 200 and 3000 
ng/ml to assess accuracy and precision of the analytical method. All calibration and QC samples 
were extracted with the method described in the subsequent section and stored at 
(Kenmore, USA) until they were analyzed.
 
 
 
 
Figure 3.4 Calibration curve of SN79 extracted from rat plasma
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3.5.2 Selectivity 
It is important to show that a chromatographic procedure is selective for the analyte. It should be 
capable of differentiating and quantifying the analyte in presence of potential matrix components 
from plasma proteins, urine etc. Each blank sample should be checked for interference and 
selectivity must be established at the lower limit of quantification (LLOQ). 
The selectivity of the method was evaluated by comparing the chromatograms of a pool of six 
different batches of blank rat plasma samples with the corresponding spiked plasma samples to 
make sure there were no significant interfering peaks at the retention times of  SN79 and IS at 
lower limit of quantification.  
3.5.3 Linearity and lower limit of quantification (LLOQ) 
Calibration curves were calculated based on the relationship between the ratio of the peak area of 
SN79 to that of the internal standard and the theoretical concentration of analyte. The calibration 
data was processed with MassLynx 4.0 QuanLynx software. The lower limit of quantification 
was defined as the concentration of SN79 at which the response of SN79wass ten times the 
response compared to the blank response. 
3.5.4 Accuracy and precision 
For all assays, accuracy of the results is vital [262]. Accuracy may be improved by use of 
replicate sample analysis. Accuracy is defined as closeness of the mean test results to the true 
concentration of the analyte. The precision of an analytical method is a measure of closeness of 
individual test results of an analyte.  
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Intra-day accuracy and precision were evaluated by analysis of the four QC samples with six 
determinations per concentration in the same day. The inter-day accuracy and precision was 
measured over three days. Precision was measured by inter- and intra-assay % R.S.D.  
 
The accuracy was evaluated by the deviation or bias (%) of the observed concentration from the 
actual concentration.  
3.5.5 Recovery and matrix effects 
Recovery experiments were conducted as described by Z. Li. Et al. [263]. Rat plasma samples 
were spiked with SN79 at three final concentration levels (3,000, 200, and 15 ng/mL) and 
extracted in the same manner as the plasma study samples (n = 5) in Section 3.5.1. Then 10 µL 
(10µg/mL) of I.S. was added to the extracts and the sample was injected into the UPLC–MS 
system. The peak-area ratio of SN79 to I.S. was calculated. Standard mixtures of SN79 and I.S. 
were made in mobile phase at concentrations same as those in the rat plasma. These standards 
were directly injected into the UPLC–MS system and the peak-area ratio of SN79 to the I.S. was 
calculated. The recovery of SN79 was evaluated by comparing the peak-area ratios of SN79: I.S. 
in the rat plasma extracts to that of the standard mixtures. The matrix effect on the ionization of 
the analytes was evaluated by comparing the peak areas of the analytes dissolved in the blank 
sample (the final solution of blank plasma after extraction and dissolution) with that dissolved in 
the mobile phase. Three different concentration levels of SN79 (3,000, 200, and 15 ng/mL) and 
the I.S. were evaluated by analyzing six samples at each level. The blank plasmas used in this 
Recovery, % RE = (Area_of_pre_extraction_spike / Area_of_post_extraction_spike)*100 [2] 
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study were six different batches of blank rat plasmas. If the ratio is <85% or >115%, an 
exogenous matrix effect is implied. [50]. Matrix effect was calculated as follows: 
 
 
3.5.6 Stability 
Anticipating the actual storage conditions the samples might encounter, the stability of the 
analyte in the matrix should be evaluated after long term (frozen at intended storage temperature) 
and short-term storage and upon subjecting to freeze thaw cycles. The QC samples (n=6) at four 
final concentrations (3,000, 200, 15, and 5 ng/mL) and a volume of 1 mL were stored in micro-
centrifuge tubes and used to study stability.  
For freeze-thaw stability, unprocessed QC samples were subjected to three freeze-thaw cycles. 
Each cycle lasts for 24 h. At the end of each cycle, the samples were processed, analyzed and 
compared with the freshly prepared QC samples. When completely thawed, the samples were 
refrozen for 12–24 h under the same conditions. After three cycles, the percent loss of the analyte 
was determined by comparing the concentrations with those obtained before freezing.  
For the short-term stability test, the QC samples at the same four concentrations were thawed at 
room temperature and kept at this temperature from 4 to 24 h which exceeds the routine 
preparation time of the samples. At different time points, the samples were processed, analyzed 
and compared with the freshly prepared QC samples.  
Matrix effect, %ME = (Area_of_post_extraction_sample/Area_of_standard)*100 [2] 
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Long term stability is studied to determine how long samples can be stored at −20 °C (Kenmore, 
USA) before they undergo degradation. This data is helpful while storing pharmacokinetic study 
samples before they are analyzed. The duration of this study was set as 30 days to reflect the 
possible time it might take before analyzing samples collected during pharmacokinetic studies. 
QC samples were stored at −20 °C (Kenmore, USA) for 30 days. The samples were then 
processed, analyzed and compared with the freshly prepared QC samples.  
3.6 Results 
3.6.1 Method Validation in Rat Plasma 
3.6.1.1 Selectivity 
UPLC/MS analysis of the plasma samples showed no endogenous peak interference with the 
quantification of SN79 and the internal standard. Representative chromatograms of blank rat 
plasma spiked with SN79 and internal standard, blank plasma and extracted plasma samples are 
shown in Figure 3.2 and 3.3.3.6.1.2 Linearity and lower limit of quantification 
A calibration curve was constructed based on the working standard SN79 solutions at 10 
concentrations in the range of 5-5000 ng/mL (Table 3.1) The ratio of peak areas of SN79 to that 
of the IS was used for the quantification of SN79. Linear regression was applied to the 
calibration curve to determine the correlation coefficient, r2. The calibration curve (Figure 2.4) 
was determined to be linear over the concentration range from 5 to 5000 ng/mLwith a correlation 
coefficient of 0.9999, indicating good linearity. The calibration/ linear equation was Y = 0.005X - 
0.00041. Each standard point was back calculated with the calibration. The non-zero standards 
showed less than 20% deviation at the LLOQ and less than 15% deviation at all other 
75 
 
concentration levels. The calibration range was selected according to the concentrations 
anticipated in the samples to be determined. The final calibration range was between 5–
5,000 ng/mL. The lower limit of quantification was 5 ng /mL. Calibration curve and data are 
presented in Figure 3.4 and Table 3.1. 
3.6.1.3 Accuracy and precision 
The results of the accuracy and precision tests at the four concentrations are presented in Table 
3.2 and Table 3.3 respectively. The QC test concentrations measured after analysis using 
UPLC/MS were compared against true concentrations using a calibration curve constructed on 
the same day. For inter-day accuracy and precision, the same procedure as above was repeated 
for three consecutive days. Accuracy was measured in terms of % recovery and should not 
deviate from the mean value by more than 20% at LLOQ and 15% at all other concentrations. 
Similarly, precision values measured as % relative standard deviation (RSD) should not exceed 
20% for LLOQ and 15% at all other concentrations. Intraday precision values for LLOQ, low 
QC, mid QC and high QC were found to be 8.71%, 5.44 %, 0.42% and 3.61%. These values are 
well within the above-mentioned acceptance criteria.  Intra-day accuracy values were in the 
range of 93.7 – 101.82%. For inter-day, precision values for LLOQ, low QC, mid QC and high 
QC were found to be 2.32%, 1.86%, 1.23% and 1.53%. These results met the acceptance criteria 
satisfactorily. Inter-day accuracy values ranged between 97.05-101.25%.  
 
3.6.1.4 Recovery and matrix effect 
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The mean recoveries of this method were 96.18 ± 2.38% at 3,000ng/ml, 94.41 ± 2.28% at 
200ng/ml and 95.22 ± 7.94% at 15ng/ml.  ANOVA was used as a statistical tool to compare the 
recovery values among three different concentrations. The results indicated that there were no 
significant differences (p<0.05) in the extraction recoveries at different concentration levels. 
Recovery values of SN79 from rat plasma were listed in Table-3.4. 
A matrix effect is defined as the direct or indirect alteration or interference in response due to the 
presence of unintended analytes or other interfering substances in the sample. It could be a 
severe problem when developing LC/MS assays. In our experiment, the matrix effect of the 
studied plasma was calculated using ratio of the response of spiked samples after extraction over 
the response of the corresponding mobile phase samples. The matrix effect was found to be -
3.82± 2.38% at 3,000 ng/ml, -5.59 ± 2.28% at 200ng/ml and -4.78 ± 7.94% at 15ng/ml. A matrix 
effect less than 15% is acceptable [50, 52]. Therefore, the matrix effects from endogenous plasma 
components on the ionization of the analytes were negligible. The chromatographic parameters 
were optimized in such a way that the analyte and the internal standard were eluted at different 
times. The absolute peak area of CM156 was used as a marker to monitor possible suppression 
effects with study samples.  
3.6.1.5 Stability 
The results of freeze-thaw, short-term and long term stabilities are presented in Table 3.5, Table 
3.6 and Table 3.7. SN79 was found to be stable after three freeze-thaw circles at four different 
concentrations. SN79 in rat plasma at four QC concentrations stored at room temperature was 
found to be stable for at least 8 h. The mean recoveries from the nominal concentrations were 
between 70 and 100% at three different concentrations.  
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Table 3.1 Calibration curve data for SN79 extracted from rat plasma
# Conc (ng/mL) 
1 5 
2 10 
3 25 
4 50 
5 100 
6 200 
7 500 
8 1000 
9 3000 
10 5000 
 
 
Figure 3.4 Calibration curve of SN79 extracted from rat 
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RT (min) Area Response 
1.06 1404 0.024 
1.06 3146 0.050 
1.06 8850 0.124 
1.06 14790 0.249 
1.06 29759 0.499 
1.06 57431 0.996 
1.06 137681 2.491 
1.06 307714 4.983 
1.06 1023848 15.044 
1.06 1696067 25.111 
plasma
 
 
Measured Conc 
(ng/mL) 
4.91 
10.03 
24.96 
49.94 
99.92 
199.27 
498.26 
996.77 
3008.85 
5022.24 
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Table 3.2 Intra-day precision and accuracy of SN79 in rat plasma 
Time (hr) Concentration (ng/mL) 
3000 200 15 5 
0 3098.94 200.05 15.07 4.94 
4 2852.13 199.09 15.34 4.80 
6 3041.68 200.06 14.34 4.08 
8 3049.09 201.15 16.34 4.92 
Mean 3010.46 200.09 15.27 4.69 
S.D. 1.08 0.84 0.83 0.41 
% RSD 3.61 0.42 5.44 8.71 
Recovery 100.35 100.04 101.82 93.7 
 
 
 
Table 3.3 Inter-day precision and accuracy of SN79 in rat plasma 
DAY Concentration (ng/mL) 
3000 200 15 5 
1 3007.23 204.00 14.04 4.95 
2 3083.10 201.26 14.42 5.18 
3 2998.94 199.05 15.07 5.05 
Mean 3029.76 201.44 14.51 5.06 
S.D. 4.64 2.48 0.27 0.12 
% RSD 1.53 1.23 1.86 2.32 
Recovery 100.99 100.63 97.05 101.25 
  
 
 
 
RSD – standard deviation/mean;   
Recovery = 1-(nominal concentration-measured concentration)/nominal 
concentration. 
RSD – standard deviation/mean;   
Recovery = 1-(nominal concentration-measured concentration)/nominal 
concentration. 
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Table 3.4 Recovery values of SN79 from rat plasma (n=3) 
Actual 
Concentration 
(ng/mL) 
Measured 
Concentration 
(ng/mL) 
Mean S.D. 
% 
RSD 
Recovery 
3000 
2912 
2885 2.38 2.48 96.18 2804 
2940 
200 
193 
189 2.28 2.41 94.41 189 
184 
15 
14 
14 7.94 8.34 95.22 14 
16 
    SD – standard deviation; RSD – standard deviation/mean;   
 
Table 3.5 Stability of SN79 in rat plasma after three freeze thaw cycles 
Concentration 
(ng/mL) 
Recovery 
(%) ± S.D. 
R.S.D. (%) 
3000 94.45±2.73 2.89 
200 98.28±8.36 8.50 
15 103.16±1.28 1.24 
5 102.33±1.27 1.25 
SD – standard deviation; RSD – standard deviation/mean;   
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Table 3.6 Short term stability of SN79 in rat plasma 
Time 
(hr) 
Concentration (ng/mL) 
3000 200 15 5 
Recovery 
(%) ± S.D. 
R.S.D. 
(%) 
Recovery 
(%) ± S.D. 
R.S.D. 
(%) 
Recovery 
(%) ± S.D. 
R.S.D. 
(%) 
Recovery 
(%) ± S.D. 
R.S.D. 
(%) 
4 
101.10 + 
8.05 
7.96 96.29 + 
8.53 
8.86 92.82 + 
8.61 
9.27 90.06 + 
3.09 
3.43 
6 
80.46 + 
3.20 
3.98 
83.87 + 
2.66 
3.17 
88.88 + 
3.38 
3.80 
86.38 + 
1.23 
1.42 
8 80.75 + 
8.03 
9.94 83.42 + 
3.70 
4.44 83.93 + 
1.06 
1.27 82.56 + 
6.17 
1.34 
SD – standard deviation; RSD – standard deviation/mean;   
 
 
Table 3.7 Long term stability of SN79 in rat plasma after 30 days 
Concentration 
(ng/mL) 
Recovery (%) ± S.D. R.S.D. (%) 
3000 88.36 + 0.83 0.94 
200 92.78 + 2.57 2.77 
15 91.60 + 2.98 3.26 
5 92.53 + 1.87 1.73 
           SD – standard deviation; RSD – standard deviation/mean;   
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CHAPTER IV: PHARMACOKINETICS OF SN79 IN RATS 
4.1 Experimental  
4.1.1 Materials 
HPLC grade acetonitrile, methanol, chloroform, water, monobasic potassium phosphate, 
potassium chloride, sodium hydroxide, hydrochloric acid  were purchased from Fisher (Fair 
lawn, NJ, USA). Reagent grade trifluoroacetic acid, pepsin (derived from porcine stomach 
mucosa, 800-2500 units/mg protein), pancreatin, potassium biphthalate, boric acid, ammonium 
acetate, nicotinamide adenine dinucleotide phosphate, glucose-6-phosphate dehydrogenase, 
glucose-6-phosphate and magnesium chloride were purchased from Sigma-Aldrich (95%, St. 
Louis, MO, USA). Drug-free rat plasma was bought from Innovative Research Inc. (Southfield, 
MI, USA). Rat liver microsomes were purchased from CellzDirect Inc. (Durham, NC, USA). 
Sodium chloride (0.9% w/v) was purchased from Abbott Laboratories (North Chicago, IL, 
USA). SN79 and CM156 were supplied by Dr. Christopher R. McCurdy’s group from the 
Department of Medicinal Chemistry at the University of Mississippi. The purity of the 
compounds was proved to be over 98% by H1-NMR and C13-NMR. 
Collision gas used in mass spectrophotometer was argon supplied by nexAir (Memphis, TN, 
USA). Nitrogen was used as desolvation and cone gas for mass spectrophotometer. Nitrogen 
generator used in our laboratory is from Peak Scientific (Billerica, MA, USA). 
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Other equipment used for sample processing includes Accuspin Micro 17R centrifuge (Fisher 
Scientific, U.S.A), VWR Signature® pulsing vortex mixer (VWR Scientific Inc., U.S.A), vacuum 
oven (Precision, Jouan. Inc, USA) and Kenmore (USA) refrigerator. 
4.2 Liquid chromatography and Mass spectrometry 
SN79 
A Waters Acquity UPLC system was used (Milford, MA, USA). Chromatographic separations 
were performed on a Waters Acquity UPLCTM BEH C18 column (1.7 µm, 2.1 × 50 mm). The 
mobile phase consisted of acetonitrile: methanol (95:5) and 0.3% trifluoroacetic acid (50:50, 
v/v). The flow rate was 0.2 mL/min, the sample injection volume was 10 µL, and the duration of 
the run was 2 min. 
The mass spectrometry equipment consisted of a Waters Micromass Quattro MicroTM triple-
quadrupole system (Manchester, UK). The mass spec system was controlled by version 4.0 of 
Mass Lynx software. Ionization was performed in the positive electro spray mode. Mass spec 
conditions were the following: capillary voltage 4.69 kV, cone voltage 51V, extractor voltage 
4V, RF lens voltage 0.3V. The source and desolvation temperatures were maintained at 120°C 
and 450 °C, respectively, and the desolvation and cone gas (nitrogen) flows were held at 380.2 
and 95.8 L/hr, respectively. The selected mass-to-charge (m/z) ratio transition of SN79 [M+H] + 
used in the single ion reaction (SIR) was m/z: 412.3, respectively. The dwell time was set at 500 
ms. 
4.3 Physicochemical parameters 
As mentioned in Section 2.3 of Chapter 2, close scrutiny of the physicochemical parameters may 
help predict oral bioavailability of a new chemical entity prior to the commencement of 
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laboratory experiments. Efficient oral absorption is governed by the ability of the drug to 
dissolve completely and become available to the intestinal mucosal surface to traverse the 
epithelium. Dissolution is determined by the highly interdependent influences of aqueous 
solubility, ionizability (pKa), and lipophilicity (octanol/water log P or log D7.4). In order for a 
drug to be distributed to its site of action, it must cross at least one or more membranes. Owing 
to the largely lipophilic nature of the membrane, most of the drugs cross the membrane by virtue 
of diffusion, thereby making lipophilicity of the drug molecule a primary determinant of the rate 
of absorption. To enhance the ability of the drug to traverse both aqueous and lipid environments 
of the membrane, an understanding of the relative affinity of the drug for both phases is useful in 
predicting whether or not the drug will be absorbed across the blood–brain barrier. For this 
purpose, the partitioning of a drug between water and octanol at a constant temperature is studied 
to give the partition coefficient (P) or log P. Likewise, log P is a crucial determinant of passive 
membrane partitioning, influencing permeability opposite to its effect on solubility (i.e. higher 
log P value increases permeability while reducing solubility). In light of this proportionality, a 
lop P value in the range of 0.5 to 2.0 is recommended for oral absorption [259].  
Certain other characteristic properties of the drug such as degree of ionization also play a crucial 
role in determining its ability to penetrate membranes. Ionized molecules possess an electrostatic 
charge, thereby dissolve preferentially in water because they tend to associate with a similarly 
charged environment [264]. Alternately, un-ionized molecules have no net charge or polarity and 
thus are lipophilic. Also, the pH of the environment is instrumental in determining the ability of a 
drug to diffuse into and across lipid membranes. The effect of pKa in oral absorption is 
correlated to the pH dependence of drug permeability across membrane barriers and that of drug 
solubility in luminal fluid.  
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4.3.1 cLog P and pKa determination 
The cLog P value was calculated with ACD labs software. The pKa and cpKavalues of the 
compound were determined by potentiometric titration method and ACD labs software. The 
conventional titration technique was used to determine the pKa value of SN79. A solution of 
sodium hydroxide at a concentration of 0.01M was prepared and pH measured using a Mettler 
Toledo SevenEasyTMpH meter S20 as 11.81. Similarly, 0.01M hydrochloric acid was prepared 
and the pH measured as 2.13. A solution of SN79 was prepared by adding 0.31 mg of the 
compound to 50 mL of water. The pH of the drug solution was measured at a value of 5.62 at 
room temperature (28.9 0C). The solution was ultra-sonicated for 10 minutes .To the SN79 drug 
solution, 0.1mL portions of sodium hydroxide were added and pH recorded (Mettler Toledo 
SevenEasyTMpH meter S20) until it became relatively constant. Subsequently, 0.1 mL portions of 
hydrochloric acid were added and pH recorded till it became constant. A titration curve was 
plotted as pH versus volume of base/acid added. The intersection point of these two curves is 
noted as the pKa value of the compound. 
4.3.2 Aqueous and pH dependent Solubility 
Solubility of SN79 was calculated in water (pH-6.98) and in buffers at pH 1.2, 3.0, 5.0, 7.4 and 
9.0 using shaking flask method [265] and ACD labs software. Excess compound was added to 
the 0.5 mL of solvent and placed in glass vials and capped. Presence of excess compound was 
established by visual examination. The samples were placed in a shaking water bath (Fisher 
Scientific, USA) at 100 rpm (at 25ºC).  Samples were analyzed after 24 and 48 hr.  Calibration 
curve was run using fresh standard solutions of SN79. The calibration/ linear equation was used 
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to measure the amount of SN79 present in the solubility samples to calculate solubility. Buffers 
were prepared according to protocol mentioned in the US Pharmacopeia.  
• Buffer of pH-1.2 was prepared by taking 12.5 mL of 0.2M potassium chloride solution 
and 21.25 mL of 0.2M hydrochloride solution in a 50 mL volumetric flask. Water was 
added to bring up the volume to 50 mL. 
• Buffer of pH-3.0 was prepared by taking 12.5 mL of 0.2M potassium biphthalate solution 
and 5.575 mL of 0.2M hydrochloride solution in a 50 mL volumetric flask. Water was 
added to bring up the volume to 50 mL. 
• Buffer of pH-5.0 was prepared by taking 12.5 mL of 0.2M potassium biphthalate solution 
and 5.65 mL of 0.2M sodium hydroxide solution in a 50 mL volumetric flask. Water was 
added to bring up the volume to 50 mL. 
• Buffer of pH-7.4 was prepared by taking 12.5 mL of 0.2M potassium phosphate, 
monobasic solution and 9.775 mL of 0.2M sodium hydroxide solution in a 50 mL 
volumetric flask. Water was added to bring up the volume to 50 mL. 
• Buffer of pH-9.0 was prepared by taking 12.5 mL of 0.2M boric acid and potassium 
chloride solution and 5.20 mL of 0.2M sodium hydroxide solution in a 50mL volumetric 
flask. Water was added to bring up the volume to 50 mL. 
4.4 pH dependent Stability 
The stabiliy of SN79 was estimated in various buffers in the pH range of 1.2- 9.0 at -20ºC  
(Kenmore Refrigerator, USA), 25ºC and 37ºC (Fisher Scientific, USA). The compound was 
dissolved in HPLC water to obtain a known concentration of 1mg/mL. From this solution, 
100ug/mL and 10ug/mL solutions were made in water. A hundred microliter sample of 10ug/mL 
solution was added to 0.9mL of the buffers in triplicate and placed at -20ºC, 25ºC and 37ºC. The 
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stability samples were analyzed on zero day and after 24 hr, 48 hr, 7 days, 15 days, 30 days and 
45 days. Calibration curve was run using fresh standard solutions of SN79 on each day of 
analysis. The calibration/ linear equation was used to measure the amount of SN79 present in the 
stability samples to calculate percent remaining of the compound. Buffers were prepared 
according as mentioned in Section 4.3.2. 
4.5 Stability in Stimulated Gastric and Intestinal Fluids 
The stability of the compound in simulated gastric and intestinal fluids helps us better understand 
drug plasma levels in the gastrointestinal tract and the role of hepatic metabolism. The stability 
of SN79 was evaluated in stimulated gastric (SGF) and intestinal fluids (SIF). The compound 
was dissolved in water to obtain a known concentration of 1mg/mL. From this solution, 
100ug/mL and 10ug/mL solutions were made in water. A five hundred microliter of 10ug/mL 
solution was added to 0.5mL of SIF and SGF in capped glass vials and placed at 37ºC in a water 
bath (Fisher Scientific, USA). Simulated gastric fluid samples were collected at zero min and 60 
min. Simulated intestinal fluid samples were collected at zero min, 60 min, 120 min and 180 
min. The samples were analyzed on UPLC/MS for SN79 content. The stability of the compound 
in simulated gastric and intestinal fluids was calculated. Simulated gastric and intestinal fluids 
were prepared in accordance with the US Pharmacopeia. 
• Simulated gastric fluid is prepared by dissolving 0.1g of sodium chloride and 0.16g of 
purified pepsin (derived from porcine stomach mucosa, 800-2500 units/mg protein) in 
0.35mL of hydrochloric acid. The resulting solution is diluted with water to 50mL with a 
final pH of 1.2. 
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• Simulated intestinal fluid is prepared by dissolving 0.34g of potassium phosphate, 
monobasic in 12.5mL of water. To this, 3.85mL of 0.2N sodium hydroxide, 25mL of 
water and 0.5g of pancreatin are added and pH of the resulting solution is adjusted to 
6.8±0.1 using either 0.2N sodium hydroxide or 0.2N hydrochloride solution. The final 
volume is made up to 50mL using water with a pH of 6.8. 
 
The relative difference (RD) between the amount added and the amount after incubation was 
calculated as follows [266-267]:  
RD = [(Ci– Cf) /Ci] ×100% 
Where Ci is the amount of drug at zero time and Cf is the amount after incubation.  
Significant difference (>5%) of a drug assessed in this manner could suggest potential instability 
in the GIT [266].  
4.6 In vitro Plasma Protein Binding Studies 
The plasma protein binding capability of SN79 was studied in vitro at specific concentrations in 
the range of 5-5000 ng/ mL. The desired concentrations were obtained by diluting with rat 
plasma. The compound was dissolved in water to obtain a known concentration of 1 mg/mL. 
From this solution, 0.1mL was taken and diluted with 0.9 mL of water to obtain a final 
concentration of 100 ug/mL solution. This solution was further diluted with rat plasma to obtain 
solutions with final concentrations of 0.5ug/mL and 1 ug/mL respectively. These plasma samples 
were placed in Centrifree® devices (Millipore 30,000 NMWL) and incubated at 37ºC for 30 min. 
The samples were then centrifuged for 10 min at 1000 g and ultrafiltrates were collected. To 
100µL of ultrafiltrate, 100 µL of acetonitrile was added along with 10 µL of internal standard 
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solution (10 µg/mL of CM156). The samples were vortex mixed for 2 min and centrifuged 
(Accuspin Micro 17R centrifuge, Fisher Scientific, U.S.A) for 10 min. The supernatant collected 
was filtered using a 0.45 µM filter (Waters 13 mm GHP 0.45 µm) and analyzed using 
UPLC/MS. Nonspecific binding was determined and incorporated in the calculation of plasma 
protein binding values. 
Percent of free drug concentration was calculated as follows. Percent unbound drug 
concentration fu is given by [268]: 
fu= [Cf/ Ci– Cf] × 100 
Where Ci = intial concentration of drug, Cf= final concentration of free drug, fu = percent 
unbound drug concentration. 
4.7 In vitro GIT Permeation Studies 
The absorption pattern of SN79 across various segments of GIT was studied in vitro. Animals 
were anesthetized using ketamine and the duodenum, jejunum and ileum were harvested from 
male Sprague dawley rats and stored in saline. Permeability study was performed using 
PermeGear diffusion apparatus (Bethlehem, PA).  The tissues were cut along the mesenteric line 
and mounted between standard 3mm side-by-side diffusion cells. Absorption was studied from 
mucosal to serosal side as well as serosal to mucosal side at 37ºC. The donor and receptor cells 
were filled with ammonium acetate buffer (pH adjusted to 7.4) while stirring throughout the 
study with magnetic stir bar.  The compound was dissolved in ammonium acetate and added to 
the donor cell. Permeability was studied at two different concentrations (0.25mg/mL and 
0.5mg/mL) in the range of 5-5000ng/ mL. Aliquots of 0.2mL were withdrawn at pre-determined 
90 
 
time points and immediately replaced with equal amount of blank buffer. Samples were analyzed 
using UPLC/MS.  
4.8 In vitro Metabolic Stability 
Phase-I metabolism stability of SN79 was studied in rat, mouse and human liver microsomes. 
The total incubation volume was 200 µL. Incubation mixture consisted of liver microsomal 
protein (1 mg/mL), SN79 (10 µM), 100 mM ammonium acetate buffer (pH adjusted to 7.4) and 
NaDPH regenerating system. The NaDPH regenerating system was prepared by taking 
nicotinamide adenine dinucleotide phosphate (1mM, pH-7.4), glucose-6-phosphate (10mM), 
magnesium chloride (10mM) and glucose-6-phosphate dehydrogenase (2U/mL). The NaDPH 
reagents were dissolved in 1 mL of 100 mM ammonium acetate buffer in an eppendorf tube. 
Ammonium acetate buffer was prepared by addition of 385 mg of ammonium acetate to 50 mL 
of water to attain a final concentration of 100 mM. In clearly marked 20mL wide mouthed vials 
(Fisher Scientific, FairLawn, NJ, USA), 150µL of buffer, 20µL of drug solution (1µg/mL) and 
10µL of  liver microsomes were added and equilibrated for 5 min in a water bath (Fisher 
Scientific, USA) at 37ºC. The addition of 20µL of the NaDPH regenerating system triggered the 
reaction. Reaction was then terminated at 0, 5, 10, 15, 20, 30, 45, 60 and 90 min with 0.2 mL of 
ice cold ACN and the samples were then held on the bench until further processing. The samples 
were centrifuged (Accuspin Micro 17R centrifuge, Fisher Scientific, U.S.A) at 4°C for 15 
minutes at 12000 rpm and the supernatant analyzed using UPLC/MS for residual SN79 content. 
The solvent controls were also processed similarly.  
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The elimination half-life (T1/2) was calculated as follows: 
t1/2 = − 0.693/k 
Where k is the slope of the line obtained by plotting natural logarithmic percentage (Ln %) of 
SN79 remaining in the reaction mixture versus incubation time (minutes). 
Intrinsic clearance (CL’int, mL/min/kg) was calculated from the following equation [269]: 
CL’int =     0.693       mL incubation  45mg microsomes       45g liver 
    In vitro t1/2         mg microsomes           g liver            kg bw 
 
4.9 Animal studies conducted in fasted state 
The SN79 compound was administered to male Sprague dawley rats to determine its 
pharmacokinetic profile. All experimental procedures were approved and performed in 
accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC) at 
the University of Mississippi under Protocol No-08-008. Pre-cannulated Sprague dawley rats 
(175-199g) were obtained from Harlan Laboratories (Indianapolis, IN). During the study, rats 
were housed in standard metabolism cages and allowed free movement and water ad libitum. 
Intravenous (IV) formulations and oral (p.o.) formulations were prepared on the same day of the 
study. The formulations were sonicated to ensure complete solubilization of SN79 before dosing 
to the animals. The IV solutions were administered via the jugular vein cannula, after which the 
cannula was flushed with 0.2 ml heparinized saline to ensure complete administration of the 
dose. The oral (p.o.) formulation was gavage dosed to the rats. After administration, the tube 
containing the drug solution was rinsed with 0.5 mL saline, which was also administered to the 
rat. The remaining formulation was assayed using UPLC/MS. Blood samples were collected 
x x x 
92 
 
using the indwelling cannula. An initial blood volume of 0.05 mL was withdrawn to clear the 
line of heparinized saline. Using a fresh syringe 0.25 mL of blood was withdrawn and placed in 
an anti-coagulant coated micro-centrifuge tube. The cannula was then flushed with 0.25 ml of 
heparinized saline. The blood samples were stored in ice until centrifugation. Rat plasma was 
separated by centrifugation (Eppendorf 5415C centrifuge) at 3000 g for 10 min at 4°C and stored 
at -20°C (Kenmore Refrigerator, USA) until analysis by UPLC/MS. 
Urine and fecal samples were collected at various time intervals during the study period. All 
samples were stored at -20°C (Kenmore Refrigerator, USA) until analyzed by UPLC/MS. 
 
4.9.1 Heparinized Saline 
A sodium chloride solution with a concentration of 0.9% w/v was prepared in HPLC grade water 
and auto-claved using the dry heat setting for 20 min. After sterilizing, 5 mg of heparin sodium 
salt was added to 100mL of sodium chloride solution to obtain a final of 10U/mL concentration 
of heparin. 
 
4.9.2 Formulations 
All the formulations were prepared afresh on the day of the experiment. Both IV and oral 
formulations were vortex-mixed and sonicated till the compound was completely dissolved in the 
vehicle. 
 
4.9.2.1 Intravenous formulation 
The IV formulation of SN79 was prepared in saline. SN79-di-HCl (12.03 mg) was dissolved in 3 
mL of saline to produce a final concentration of SN79 equivalent to 4 mg/mL. The solution was 
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ultra-sonicated for 2 minutes to dissolve the compound completely. The intravenous formulation 
was administered to rats at a dose of 5 mg/kg.  
4.9.2.2 Oral formulation 
The oral formulation of SN79 was prepared in saline. SN79-di-HCl (28.29 mg) was dissolved in 
7 mL of saline to produce a final concentration of SN79 equivalent to 4 mg/mL. The solution 
was ultra-sonicated for 2 minutes to dissolve the compound completely. The oral formulation 
was administered at a dose equivalent to 20 mg/kg of SN79.  
4.9.3 Formulation stability 
The stability of the IV and oral formulations was conducted in rat plasma. During this study we 
looked for any precipitation or degradation of the compound in presence of saline. A time period 
of three days was selected, which will encompass the entire animal study period. A five hundred 
micro-liter of the formulations, both IV and oral, were incubated in 1 mL of rat plasma in capped 
glass vials at a temperature of 37° C. From this stock, 100 µL of plasma was processed for 
analysis everyday for 3 days to assess the stability of the compound in rat plasma. Extraction 
procedure was same as mentioned in Section 3.5.1.  
4.9.4 Processing of Plasma samples 
4.9.4.1 Standards preparation 
SN79 di-hydrochloride was used to prepare standard solutions. To prepare a stock solution of 
concentration 1 mg/ml of SN79, 1.18 mg of SN79 di-hydrochloride was dissolved in 1mL of 
HPLC grade water. Further dilutions were made using HPLC grade water to get final 
concentrations of 50, 100, 150, 500, 1,000, 2,000, 5,000, 10,000, 30,000 and 50,000ng/ml 
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respectively. The internal standard, CM156 was prepared at a concentration of 10 µg/ml in 
water. To prepare the standards, 80 µL of blank rat plasma was taken, to which 10 µL each of 
standard stock solution was added to get final concentrations of 5, 10, 15, 50, 100, 200, 500, 
1,000, 3,000 and 5,000ng/ml. To these standard solutions, 10 µL of the internal standard (10 
µg/ml) was added to get a final volume of 100 µL. Chloroform (500 µL) was used as the 
extraction solvent, and the micro-centrifuge tubes were vortexed for 10 minutes. The samples 
were then centrifuged for 20 minutes at 10,000 rpm. Supernatant (400µL) was collected and 
evaporated to dryness in a vacuum oven (Precision, Jouan. Inc, USA). To the dried samples, 100 
µL of mobile phase was added and vortexed for 2 minutes. All the samples were filtered with a 
0.2µm filter (Waters 13 mm GHP 0.45 µm) and analyzed using UPLC/MS. 
Quality Control (QC) samples were prepared separately at concentrations of 5, 15, 200 and 
3,000ng/ml to assess accuracy and precision of the assay method. All of the calibration and QC 
samples were extracted using the method described in the subsequent section and stored at –
20°C (Kenmore Refrigerator, USA) until analysis. 
4.9.4.2 Sample preparation 
An aliquot of 90 µL of rat plasma and 10 µL of the internal standard solution were placed in an 
eppendorf micro-tube for processing. Chloroform was used as the extraction solvent. Five 
hundred micro-liter of chloroform was added to these samples and the micro-centrifuge tubes 
were vortexed for 10 minutes on VWR Signature® pulsing vortex mixer (VWR Scientific Inc., 
U.S.A). The samples were centrifuged at 3000 rpm for 20 minutes using an Accuspin Micro 17R 
centrifuge (Fisher Scientific, U.S.A). The organic phase (400 µL) was transferred into 1.5 
mLeppendorf tubes (Fisher Scientific, U.S.A) and dried in a vacuum oven (Precision, Jouan. Inc, 
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USA) at 25 oC. To the dried samples, 100 µL of mobile phase was added and vortex mixed for 2 
minutes. All the samples were filtered with a 0.2 µm syringe filter (Waters 13 mm GHP 0.2 µm) 
and analyzed using the UPLC/MS. 
4.9.5 Processing of Urine samples 
4.9.5.1 Standards preparation 
SN79- di-hydrochloride was used to prepare the standard solutions. To prepare a stock solution 
of concentration 1 mg/ml of SN79, 1.18 mg of SN79 di-hydrochloride was dissolved in HPLC 
grade water. Further dilutions were made using HPLC grade water to get final concentrations of 
50, 100, 150, 500, 1,000, 2,000, 5,000, 10,000, 30,000 and 50,000 ng/ml. The internal standard 
CM156, was prepared at a concentration of 10 µg/ml in HPLC grade water. To prepare the 
standards, 80 µL of blank rat plasma was taken, to which 10 µL each of standard stock solution 
was added to get final concentrations of 5, 10, 15, 50, 100, 200, 500, 1,000, 3,000 and 5,000 
ng/ml. To these standard solutions, 10 µL of internal standard (10µg/ml) was added to get a final 
volume of 100 µL. Chloroform was used as the extraction solvent. Five hundred micro-liter of 
chloroform was added to these samples and the micro-centrifuge tubes were vortexed for 10 
minutes on VWR Signature® pulsing vortex mixer (VWR Scientific Inc., U.S.A). The samples 
were centrifuged at 3000 rpm for 20 minutes using an Accuspin Micro 17R centrifuge (Fisher 
Scientific, U.S.A). The organic phase (400 µL) was transferred into 1.5 mLeppendorf tubes 
(Fisher Scientific, U.S.A) and dried in a vacuum oven (Precision, Jouan. Inc, USA) at 25 oC. To 
the dried samples, 100 µL of mobile phase was added and vortex mixed for 2 minutes. All the 
samples were filtered with a 0.2 µm syringe filter (Waters 13 mm GHP 0.2 µm) and analyzed 
using the UPLC/MS. Quality Control (QC) samples were prepared separately at concentrations 
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of 5, 15, 200 and 3000 ng/ml to assess accuracy and precision of the assay method. All 
calibration and QC samples were extracted with the method described in the section 3.5.1 and 
stored at -20 °C (Kenmore Refrigerator, USA) until analysis. 
4.9.5.2 Sample preparation 
The frozen urine samples were thawed at room temperature. Rat urine (90 µL) and 10 µL of the 
internal standard with 10% of trifluoroacetic acid were transferred into an eppendorf tube and 
vortex mixed (VWR Signature® pulsing vortex mixer, VWR Scientific Inc., U.S.A) for 2 min. 
The samples were centrifuged (Accuspin Micro 17R centrifuge, Fisher Scientific, U.S.A) for 10 
min at 10,000 rpm and analyzed using UPLC/MS. 
4.9.6 Processing of Feces samples 
An accurately weighed amount of feces (1 mg) was dried, powdered by mortar and pestle and 
dissolved in water. After vortex mixing (VWR Signature® pulsing vortex mixer, VWR Scientific 
Inc., U.S.A) for 10 min, the samples were centrifuged (Accuspin Micro 17R centrifuge, Fisher 
Scientific, U.S.A) at 10,000 rpm for 20 min and the supernatant was analyzed using UPLC/MS. 
4.9.7 Processing of Tissue samples 
After allowing the tissues to thaw at room temperature, the tissue samples were washed with 
saline and homogenized in 10mM ammonium acetate (pH-7.4) containing 0.25M sucrose. The 
homogenates were centrifuged at 10,000 rpm for 20 min. The supernatant was collected and 
filtered with a 0.45µm syringe filter (Waters 13 mm GHP 0.45µm) prior to UPLC/MS analysis. 
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4.10 Animal studies conducted in fed state 
In addition to pharmacokinetic studies conducted in fasted state in Section 4.10, studies were 
also done in fed state laboratory animals. In this study, the animals were given access to food and 
water ad libitum 3.5 hr after drug administration. All experimental procedures were approved 
and performed in accordance with the guidelines of the Institutional Animal Care and Use 
Committee (IACUC) at the University of Mississippi under Protocol No-08-008. Pre-cannulated 
Sprague dawley rats (175-199g) were obtained from Harlan Laboratories (Indianapolis, IN). 
During the study, rats were housed in standard metabolism cages and allowed free movement 
and water ad libitum. 
Intravenous (IV) formulations and oral (p.o.) formulations were prepared (as mentioned in 
Sections 4.9.2.1 and 4.9.2.2) on the same day of the study. The formulations were sonicated to 
ensure complete solubilization of SN79 before dosing to the animals. The IV solutions were 
administered via the jugular vein cannula, after which the cannula was flushed with 0.2 ml 
heparinized saline to ensure complete administration of the dose. The oral (p.o.) formulation was 
gavage dosed to the rats. After administration, the tube containing the drug solution was rinsed 
with 0.5 mL saline, which was also administered to the rat. The remaining formulation was 
assayed using UPLC/MS.  
Blood samples were collected using the indwelling cannula. An initial blood volume of 0.05 mL 
was withdrawn to clear the line of heparinized saline. Using a fresh syringe 0.25 mL of blood 
was withdrawn and placed in an anti-coagulant coated micro-centrifuge tube. The cannula was 
then flushed with 0.25 ml of heparinized saline. The blood samples were stored in ice until 
centrifugation. Rat plasma was separated by centrifugation (Eppendorf 5415C centrifuge) at 
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3000 g for 10 min at 4°C and stored at -20°C (Kenmore Refrigerator, USA) until analysis by 
UPLC/MS. 
Urine and faeces samples were collected at various time intervals during the study period. All 
samples were stored at -20°C (Kenmore Refrigerator, USA) until analyzed by UPLC/MS. 
 
4.10.1 Heparinized Saline 
A sodium chloride solution with a concentration of 0.9% w/v was prepared in HPLC grade water 
and auto-claved using the dry heat setting for 20 min. After sterilizing, 5 mg of heparin sodium 
salt was added to 100mL of sodium chloride solution to obtain a final of 10U/mL concentration 
of heparin. 
 
4.10.2 Formulations 
All the formulations were prepared afresh on the day of the experiment. Both IV and oral 
formulations were vortex-mixed and sonicated till the compound was completely dissolved in the 
vehicle. 
 
4.10.2.1 Intravenous formulation 
The IV formulation of SN79 was prepared in saline. SN79-di-HCl (12.03 mg) was dissolved in 3 
mL of saline to produce a final concentration of SN79 equivalent to 4 mg/mL. The solution was 
ultra-sonicated for 2 minutes to dissolve the compound completely. The intravenous formulation 
was administered to rats at a dose of 5 mg/kg.  
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4.10.2.2 Oral formulation 
The oral formulation of SN79 was prepared in saline. SN79-di-HCl (28.29 mg) was dissolved in 
7 mL of saline to produce a final concentration of SN79 equivalent to 4 mg/mL. The solution 
was ultra-sonicated for 2 minutes to dissolve the compound completely. The oral formulation 
was administered at a dose equivalent to 20 mg/kg of SN79.  
4.10.3 Processing of Samples 
Plasma samples, urine and fecal samples, tissue samples were processed according to the 
procedures mentioned in Sections 4.9.4, 4.9.5, 4.9.6 and 4.9.7. 
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CHAPTER V: RESULTS AND DISCUSSION 
SN79-di-HCl, a novel synthetic compound was studied to examine its potential as an effective 
agent for attenuating cocaine-induced toxicity and addiction. As part of drug discovery stage, 
various pre-formulation studies were performed to characterize the physico-chemical properties 
of the compound. The pharmacokinetic profile of the compound in male Sprague dawley rats 
was studied to establish its oral bioavailability and to determine the absorption, distribution, 
metabolism and excretion profile of SN79-di-HCl in vivo. These results will be presented here. 
5.1 cLog P and pKa 
The cLog P of SN79-di-HCl was calculated using ACD Labs software and was found to be 3.38 
indicating that it is a lipophilic compound [270]. The pKa of this compound determined using 
potentiometric method was found to be 7.9±0.14. This value suggests that it is a weak base 
(pKa>7.00) respectively [183]. Bases in the pKa range of 5 to 11 are greatly influenced by 
changes in pH and hence their absorption is pH dependent [183]. Examples are certain morphine 
analogs, chloroquine, imipramine and amitriptyline. Weak bases are better absorbed from the 
relatively alkaline conditions of the intestine where they largely exist in unionized form. Most 
drugs are given orally and absorption of such drugs is influenced by differences in luminal pH 
along the GIT, surface area per luminal volume, blood perfusion and the nature of epithelial 
membranes.
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5.2 Aqueous and pH dependent Solubility 
The solubility of SN79-di-HCl calculated at pH 1.2, 3.0, 5.0, 7.4 and 9.0 was found to be23.9, 
26.5, 28.8, 26.6 and 21.0 mg/mL respectively. The solubility of SN79-di-HCl in water was found 
to be 31.5 mg/mL which is 1 part of SN79-di-HCl in 32 parts of water. The pH of water is 
6.98.The US Pharmacopeia [271] states that a when 1 part of solvent is required to dissolve 30-
100 parts of solute, the compendia substance is ‘sparingly soluble’ in the solvent [271]. 
Likewise, SN79-di-HCl is sparingly soluble in water. The solubility of salt form depends on the 
size of the counter ion. Generally, size of the counter ion and solubility of salt bear an inverse 
relationship [183].  
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Figure 5.1 pH dependent solubility of SN79 
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Table 5.1 pH dependent solubility of SN79-di-HCl 
pH Solubility ± SEM
1.2 23.9 ± 0.01
3 26.5 ± 0.03
5 28.8 ± 0.03
7.4 26.6 ± 0.04
9 21.0 ± 0.01
 
 
5.3 pH dependent Stability 
Pre-formulation studies consist of all that it takes to characterize a drug substance to enable its 
formulation into a practical drug delivery system [272]. Drug characterization during pre-
formulation stage encompasses various studies including but not limited to determination of 
solubility, pKa, lipophilicity, stability in aqueous systems etc. Pre-formulation stability studies 
are usually the first quantitative assessment of chemical stability of a drug. Factors affecting 
chemical stability critical in rational dosage form design include temperature, pH and excipients. 
In this study, the effect of temperature and pH on the stability of SN79-di-HCl was evaluated to 
understand the influence of the highly acidic environment of the stomach. The degradation of 
SN79 in aqueous solutions followed apparent first-order kinetics, since a linear relationship was 
found between the natural logarithm of the percentage remaining and the storage time (r>0.990). 
Linear plots were obtained using the equation 
ln A = -kt + ln A0   (Eq.5.1.) 
Where A0 is the original concentration of the compound, A is the concentration at time t, and k is 
the rate constant. The experimentally determined k value was obtained from the slope of the plot 
SEM – standard deviation/mean 
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by regression analysis. The effect of pH on SN79 was determined using various buffer solutions 
in the pH range of 1.2 to 9.0. As shown in Figure 5.2., the degradation of SN79 was strongly 
correlated with the increase of pH. The pH of maximum stability occurs at pH 7.4 when placed 
in -20°C, pH 1.2 at 25°C and at pH 1.2 and 5 when placed at 37°C. Beyond the minimum, in the 
pH profile, the k value increases with increasing pH until pH 3.0 then decreases until pH 7.4. 
This might suggest an attack of hydroxyl ion on the cationic species [273]. Between pH 7.4 and 
9.0, there is an increase in the k value.  
 
 
 
The thermal effect on SN79-di-HCl degradation in buffered solutions (pH range: 1.2 to 9.0) was 
studied at three different temperatures: -20°C, 25°C and 37°C respectively.  
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Figure 5.2 Plot of the pH-rate profile of SN79-di-HCl in various buffer 
solutions; pH ranging from 1.2 to 9.0 and temperatures at -20°C, 25°C and 
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Figure 5.3 represents the Arrhenius plot of the rate (natural logarithm scale) versus the reciprocal 
of temperature (Kelvin scale), according to the equation:  
ln K = ln S – Ea/RT                                                   (Eq.5.2.) 
Where K is the pseudo-first order rate constant, S is the frequency factor, Ea is the energy of 
activation of the reaction, R is the gas constant (1.985 cal mol-1 K-1), and T is the absolute 
temperature (K°). A linear relationship was found by this plot (r>0.993) (Figure 5.3). The 
activation energy values at pH 1.2, 3.0, 5.0, 7.4 and 9.0 as calculated from the Arrhenius plot are 
provided in Table 5.2. The t90% values are provided in Table 5.3. t90% value gives the time 
required for 10% degradation of drug at any temperature. The t90% value was 3 days when the 
solution was stored at pH = 7.4, T = 25°C and that t90% value was 105 days when the temperature 
decreased to -20°C.  
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Figure 5.3 Arrhenius plots for the hydrolysis of SN79-di-HCl at various pH 
values. The pH values indicated here are those at -20°C, 25°C and 37°C. 
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Table 5.2 Activation energy for the degradation of SN79 
pH Activation energy, Ea kcal/mol 
1.2 2.8 
3 2.5 
5 3.1 
7.4 8.5 
9 3.9 
 
 
Table 5.3 Thermal and pH effects on the degradation of SN79 
pH 
Temperature 
-20°C 25°C 37°C 
t90% (days) 
1.2 12 7 2 
3.0 3 2 1 
5.0 2 2 2 
7.4 105 3 0.3 
9.0 3 2 1 
 
These results demonstrate that the stability of SN79-di-HCl in aqueous systems depends on 
several factors: temperature, pH, effect of counter-ion and ionic strength of buffers [274].  
5.4 Stability in Simulated Gastric and Intestinal Fluids 
Oral delivery is the most convenient and desirable route of drug administration. The 
bioavailability of drugs is influenced by various factors like stability in gastrointestinal fluid and 
solubility. The stability of a drug substance in gastric and intestinal fluids indicates whether or 
not drug loss from the gastrointestinal tract is via intestinal permeation or by a degradation 
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process in the gastrointestinal fluids prior to membrane absorption [266]. Permeability of a 
compound through the gastrointestinal tract is one of the most important aspects in determining 
the lead potential of a molecule [275]. In assessing drug substance permeability, the degree of 
drug degradation in the gastrointestinal fluid prior to intestinal permeation should also be 
considered. Stability in the gastrointestinal tract may be determined in vitro by incubating the 
drug substance in gastric and intestinal fluids representative of in vivo drug exposure to these 
fluids viz. 1 h in SGF and 3 h in SIF. When incubated in simulated gastric and intestinal fluids, 
SN79-di-HCl was stable throughout the duration of study as shown in tables 5.4 and 5.5. The 
relative difference values were calculated at all time points which showed no significant change 
in compound’s stability from zero time point. Since there is no significant degradation (<5%), 
the compound can be deemed stable in the gastrointestinal tract and that any drug loss might be a 
result of membrane permeation instead of gastrointestinal degradation process. Understanding 
the permeability of compounds across GIT membrane thus becomes an integral part of drug 
discovery. 
Table 5.4 Stability of SN79 in simulated gastric fluids (pH 1.2). Data expressed as mean ± 
SE (n=3); RD = relative difference 
Time (hr) SN79 (µg/ml) RD 
0 4.456 ± 0.04 -- 
60 4.458 ± 0.04 -0.04 
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Table 5.5 Stability of SN79 in simulated intestinal fluids (pH 6.8). Data expressed as mean ± 
SE (n=2); RD = relative difference 
Time (hr) SN79 (µg/ml) RD 
0 4.555 ± 0.03 -- 
60 4.567 ± 0.01 -0.25 
120 4.599 ± 0.04 -0.96 
180 4.547 ± 0.003 0.19 
 
 
5.5 In vitro Plasma Protein Binding Studies 
The reversible binding of a drug to plasma proteins is an important determinant of its 
pharmacokinetic and pharmacodynamic characteristics [276]. For certain drugs, saturable plasma 
protein binding may occur at therapeutic concentrations which can cause dose-dependent 
pharmacokinetics. The protein binding profile of SN79-di-HCl in rat plasma was evaluated in 
vitrousing ultra-filtration. The concentration dependent free fraction (Fu) of SN79 when 
incubated as SN79-di-HCl was studied. At concentrations of 0.5, 1.0, 5.0 and 10µg/mL, the Fu 
values were 3.9, 4.5, 5.4 and 8.2 respectively. The binding of SN79-di-HCl to pooled rat plasma 
protein showed a concentration dependent behavior (Figure 5.4). This indicates that if an 
increase in dose is given to subjects this would result in increased peak plasma concentrations of 
SN79-di-HCl.  
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Any changes in the extent of plasma protein binding (expressed as a change in Fu), leads to 
changes in apparent volume of distribution thereby affecting the terminal t1/2.  
Concentration dependent protein binding is given by the mathematical equation [277] 
 
Where Fu – fraction unbound 
K – affinity constant for protein binding 
P – concentration of free protein binding sites 
According to the above equation, as the concentration of drug increases, the number of free 
protein binding sites i.e. P decreases thereby increasing the Fu value. Concentration dependent 
variations in the fraction of unbound drug in plasma are most likely to occur with drugs that 
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Figure 5.4 Concentration dependent protein binding profile of SN79-di-HCl 
when incubated in rat plasma 
Fu = 1/ [1+K*P] 
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exhibit high association constant (K= 105 or 106) [278]. Plasma protein binding influences the 
movement of drug from blood to tissues. It limits drug distribution in that only free or unbound 
portion of the drug is available to enter the tissues and elicit pharmacological effects. The major 
binding protein present in plasma is albumin at a concentration of 40 g/L [279]. Since SN79-di-
HCl is a weak base, its affinity to albumin may not be high since albumin tends to exhibit 
preferential binding to acidic drugs but may bind weakly to basic drugs [279]. Aside from 
albumin, alpha-1 acid glycoprotein is another significant plasma protein with affinity for weak 
bases. Its plasma concentration is about 0.7 g/L. The extent of protein binding of a drug is either 
drug or protein concentration dependent based on the affinity and capacity of the plasma protein 
[280]. It is desirable to measure the extent of protein binding in vitro at more than two different 
concentrations, one close to the therapeutic concentration and another one close to a toxic 
concentration level.  
5.6 Animal studies 
5.6.1 Pharmacokinetics in fasted state subjects 
SN79-di-HCl pharmacokinetics was studied following the intravenous (5mg/kg) and oral 
(20mg/kg) administration of the compound to male Sprague dawley rats. The SN79 
concentration-time plots, as obtained following IV and oral dosing, are presented in Fig 5.5 and 
5.6. The pharmacokinetic parameters were estimated using non-compartmental analysis with 
Pharsight ® WinNonlinTM software version 5.2 and are presented in Tables 5.6 and 5.7.After 
intravenous and oral administration of SN79-di-HCl, close and continuous visual monitoring of 
the animals revealed that there was no severe acute toxicity response as none of the animals 
showed any signs of behavioral or neurological toxicity during the entire study period.  
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Compound C0 (µg/mL) 
AUC  
(ug-hr/mL) 
T1/2 
(hr) 
Cmax 
(µg/mL) 
Vd 
(L/kg) 
Cl_obs 
(L/hr/kg) 
SN79-di-HCl 1.40 ± 0.3 
44.5 ±  
4.8 
1.36 ± 
0.04 
1.34 ± 
0.12 
13.7 ± 
1.5 
0.18 ± 
0.01 
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Figure 5.5 Mean plasma concentration time profile of SN79-di-HCl in male 
Sprague dawley rats after intravenous administration (5mg/kg) (n=5) 
Table 5.6 Mean plasma pharmacokinetic parameters of SN79-di-
hydrochloride after intravenous administration to Sprague dawley rats 
(n=5) 
C0 – initial concentration obtained by extrapolation on y-axis; AUC – area under the curve; 
T1/2 – plasma half life; Cmax – maximum plasma concentration; MRT – mean                               
residence time; Vd – volume of distribution; CL – plasma clearance 
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Compound 
AUC  
(ug-
hr/mL) 
T1/2 
(hr) 
Cmax 
(ug/mL) 
MRT 
(hr) Vd (L/kg) 
CL 
(L/hr/kg) 
Tmax(h
r) 
SN79-di-HCl 117.3±  1.5 
7.5±  
0.7 
0.21±  
0.1 
9.9±  
1.3 
115.1±  
1.1 
0.18± 
0.02 
1.5± 
0.05 
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Figure 5.6 Mean plasma concentration time profile of SN79-di-HCl in male 
Sprague dawley rats after oral administration (20mg/kg) (n=5) 
AUC – area under the curve; T1/2 – plasma half life; Cmax – maximum plasma concentration; MRT 
– mean residence time; Vd – volume of distribution; CL – plasma clearance; Tmax – time of 
maximum plasma concentration.  
Table 5.7 Mean plasma pharmacokinetic parameters of SN79-di-hydrochloride after 
oral administration to Sprague dawley rats (n=5) 
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Average half lives of SN79-di-hydrochloride after oral and intravenous dosing were found to be 
7.51 and 1.36 hrs respectively. The different half-lives observed after IV and oral administration 
suggest different elimination rates [281]. This might be due to the presence of biologically active 
metabolites or on-going gastrointestinal absorption [282]. The maximum plasma concentration 
(Cmax) was found to be 0.21µg/mL after oral administration. When measured against the oral 
dose given to rats (20 mg/kg), the Cmaxwas low. The affinity of this compound to plasma proteins 
might affect the amount of free drug available for absorption. Results from in vitro protein 
binding studies (Section 5.5), clearly indicate the high affinity of this compound for plasma 
proteins thereby limiting its availability in the free form. The time required to reach maximum 
plasma concentration (Tmax) was 1.5 hours after p.o. dosing.  
The C0 value after intravenous administration was found to be 1.40±0.3 µg/mL. Each rat was 
given approximately 0.98mg of drug. The plasma concentration determined at one minute after 
IV administration of SN79-di-HCl was 1.34±0.1 µg/mL. The apparent volume of distribution of 
SN79-di-hydrochloride was found to be 115.1 L/kg after oral administration and 13.7 L/kg after 
intravenous administration. For a drug that is 95% protein-bound with a high volume of 
distribution [183] it redistributes into a large volume of body fluids and clinical effects may be 
negligible or insignificant.  
The compound clearance value obtained was 0.18 L/hr/kg for both intravenous and oral 
administration. Only the unbound or free drug is capable of being eliminated. It becomes 
difficult for the drug-protein complex to penetrate the metabolizing tissue (liver). The large 
molecular size also prevents it from getting filtered through the glomerulus. Such drugs are 
eliminated slowly with prolonged elimination half-lives.SN79-di-HCl showed a half-life of 7.5 
hr. Since SN79-di-HCl is a weak base (Log P>3), a major amount of drug was excreted in urine 
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rather than in feces. The urinary and feces excretion profiles are shown in Figures 5.7, 5.8, 5.9 
and 5.10. 
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Figure 5.7 Urinary excretion profile of SN79-di-HCl in male Sprague 
dawley rats after IV administration (5mg/kg) (n=5) 
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Figure 5.8 Feces excretion profile of SN79-di-HCl in male 
Sprague dawley rats after IV administration (5mg/kg) (n=5) 
Figure 5.9 Urinary excretion profile of SN79-di-HCl in male 
Sprague dawley rats after Oral administration (20mg/kg) (n=5) 
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Table 5.8 Tissue distribution of SN79-di-hydrochloride after single dose intravenous 
administration to Sprague dawley rats at 5mg/kg. 
Tissue Amount (in µg) 
% seen in 
tissue 
Heart 0.98 0.10 
Liver 3.67 0.37 
Pancreas 2.51 0.26 
Lungs 2.95 0.30 
Kidney ND ND 
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Figure 5.10 Feces excretion profile of SN79-di-HCl in male 
Sprague dawley rats after Oral administration (20mg/kg) (n=5) 
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Table 5.9 Tissue distribution of SN79-di-hydrochloride after single dose oral 
administration to Sprague dawley rats at 20mg/kg. 
Tissue Amount (in µg) 
% seen in 
tissue 
Heart 15.7 0.40 
Liver 18.9 0.50 
Lungs 4.60 0.10 
Pancreas 17.0 0.50 
Kidney 5.10 0.10 
 
After oral and intravenous dosing, there was a dose-proportional increase in the mean residence 
time values which were found to be 9.87 and 1.98 hours. When a drug is administered orally, it 
has to be absorbed into the systemic circulation. Then the drug is distributed such that 
equilibrium is established between the tissues and blood. Thereafter, the drug is excreted. So the 
drug tends to stay for longer duration in the body after p.o. dosing. However, when administered 
intravenously, the drug skips the absorption phase as it is readily available in the systemic 
circulation thereby reducing its residence time in the body by getting excreted quickly.  
From the intravenous and oral dosing of SN79-di-hydrochloride, the average oral bioavailability 
was calculated to be 65.9%. A qualitative visual examination of the data indicated the presence 
of multiple peaks in the concentration-time profile of oral SN79-di-HCl (Figure 5.6). The double 
peaks were observed at 1.50 and 7.00 hours respectively. Similar multiple peak phenomena have 
been observed for a number of structurally diverse compounds such as flurbiprofen, 
penicillamine, aspirin, furosemide and acetaminophen [285-287]. Drug absorption kinetics after 
oral administration can be influenced by several factors including membrane permeability, drug 
dissolution and gastrointestinal (GI) motility [288]. Several hypotheses based on region-
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dependent variation in absorption [289], enterohepatic recirculation [290], variable gastric 
emptying and intestinal transit rates [291] and intestinal bacterial reconversion of biliary 
metabolite [292] have been proposed to explain this behavior. Enterohepatic recycling refers to 
the circulation of bile from the liver, where it is produced, to the small intestine, where it aids in 
digestion of fats and other substances, back to the liver [293]. It has been cited as the most 
probable reason for the secondary peaks noticed following the p.o. dosing of amprenavir[294]. 
Enterohepatic recirculation was ruled out here because it would be expected that a second peak 
would also occur following intravenous administration. The absorption of cimetidine, a 
histamine H2-receptor antagonist has been shown to be lower in rat jejunum than in duodenum 
and ileum [295] and has been postulated as a possible explanation for plasma level double peaks 
in humans [296]. The time that a drug spends in the stomach and along the intestine is dictated to 
a large extent by gastric emptying and gastrointestinal motility. Relatively lower amount of most 
drugs are absorbed from the stomach compared to the small intestine, and drug is retained in the 
stomach until it is delivered to the small intestine where it is absorbed [293]. For drugs with high 
water solubility, part of the dose could be delayed in the stomach, a phenomenon called as 
Delayed Gastric Emptying. Many drugs such as cimetidine, nifedipine, avitriptran, 13C-octanoate 
and epinastine are known to have shown double peak phenomena owing to delayed gastric 
emptying. Cimetidine has always shown double peak phenomenon when gastric pH is low, but 
very rarely when it is high. The possible role of gastrointestinal motility as a major determinant 
of the phenomena of secondary maxima occurring only in the fasted state has been previously 
addressed [297-298]. Such a possibility is quite plausible since gastrointestinal motility patterns 
are unique in the fasted state in humans and dogs and is altered drastically in the fed state in the 
two species. Gastrointestinal motility in the fasted state is characterized by cyclical fluctuations 
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in contractile activity of the stomach and intestine and is composed of four phases [299]. This 
cyclical pattern of contractile activity is termed as the migrating motility complex (MMC). 
Phase-I known as basal phase is characterized by complete lack of contractions followed by a 
‘preburst activity’, which is phase-II. The contractions increase in number and activity in phase-
II. Large amplitude contractions constitute phase-IIIand they occur at the maximum frequency 
observable. Phase-IV is an intermediate phase, that is often times present or absent, acting as a 
transition period between the intense activity in phase-III and the basal quiescent phase-I. 
Woodtli and Owyang[300] reported that duodenal pH is altered with MMC phases that could 
directly affect drug absorption via a pH dependent absorption effect or indirectly modulate 
absorption by affecting phase-II duration and overall MMC. The most common reason for 
occurrence of multiple peak phenomenon following p.o. dosing is Variability of Absorption 
within different regions of the gastrointestinal tract – especially zero or minimal absorption from 
jejunum, followed by absorption from duodenum or ileum. 
The cause for appearance of multiple peak phenomenon needs further investigation. To 
understand whether or not food has any effect on the absorption of SN79-di-HCl from the gut, a 
similar pharmacokinetics study was conducted in fed state male Sprague dawley rats. 
5.6.2 Influence of food on the multiple peak phenomena observed after oral 
administration 
In addition to pharmacokinetic studies conducted in fasted state, studies were also done in fed 
state laboratory animals. In this study, the animals were given access to food and water ad 
libitum 3.5 hr after drug administration. Animals were given a p.o. dose of 20 mg/kg and IV dose 
of 5 mg/kg. Dosing, blood collection and sample processing was done as mentioned in section 
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4.10. The SN79 concentration-time plots, as obtained following IV and oral dosing, are 
presented in Fig 5.12 and 5.13. The pharmacokinetic parameters were estimated using non-
compartmental analysis with Pharsight ® WinNonlinTM software version 5.2 and are presented in 
Tables 5.10 and 5.11. After intravenous and oral administration of SN79-di-HCl, close and 
continuous visual monitoring of the animals revealed that there was no severe acute toxicity 
response as none of the animals showed any signs of behavioral or neurological toxicity during 
the entire study period.  
As shown in Fig 5.11, the multiple peak phenomena was retained in fed state subjects. As a 
result, it can be concluded that food has no effect with minimal or insignificant differences in the 
pharmacokinetic parameters (Tables 5.11 and 5.12).  
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Figure 5.11 Mean plasma concentration time profiles of SN79-di-HCl in 
fasted and fed state male Sprague dawley ratsafter oral administration 
(20mg/kg) 
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There was no significant change in AUC in fed state rats (111 µg-hr/mL) and fasted rats (117µg-
hr/mL). Likewise, there was no significant change in the pharmacokinetic parameters in 
presence/absence of food as shown in Table 5.10. 
 
 
Pharmacokinetic parameter Fasted State Fed State 
Half-life (hr) 7.50 7.80 
Volume of distribution (L/kg) 115 114 
Clearance (L/hr/kg) 0.18 0.13 
Tmax(hr) 1.50 1.52 
 
 A comparison of both the pharmacokinetic profiles, in fasted and fed state led us to conclude 
that food in the gastrointestinal tract did not alter the extent of absorption of oral SN79-di-HCl in 
male Sprague dawley rats; however the effect of food on absorption depends on the dosage form. 
These results suggest there may be other factors that induce the multiple peak phenomenons in 
the oral pharmacokinetic profile of SN79-di-HCl. Therefore, this multiple peak phenomenon 
might be due to inhibition of gastrointestinal transit but not due to fasted or fed condition of the 
rats (as discussed in Section 5.6.1.). 
 
 
 
 
Table 5.10 Comparison of pharmacokinetic parameters in fasted and 
fed state rats 
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Compound C0 (µg/mL) 
AUC (ug-
hr/mL) 
T1/2 
(hr) 
Cmax 
(µg/mL) 
Vd 
(L/kg) 
Cl_obs(L/
hr/kg) 
SN79-di-HCl 2.03 ± 0.30 
49.8 ± 
0.26 
1.53 ± 
0.19 
1.72 ± 
0.23 
13.5 ± 
0.25 
0.11 ± 
0.22 
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Figure 5.12 Mean plasma concentration time profile of SN79-di-HCl in fed state 
male Sprague dawley rats intravenous administration (5mg/kg) (n=6) 
 
Table 5.11 Mean plasma pharmacokinetic parameters of SN79-di-
hydrochloride after intravenous administration to fed state male Sprague 
dawley rats (5mg/kg) (n=6) 
C0 – initial concentration obtained by extrapolation on y-axis; AUC – area under the 
curve; T1/2 – plasma half life; Cmax – maximum plasma concentration; MRT – mean                               
residence time; Vd – volume of distribution; CL – plasma clearance 
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Compound 
AUC  
(ug-
hr/mL) 
T1/2 
(hr) 
Cmax 
(ug/mL) 
MRT 
(hr) Vd (L/kg) 
CL 
(L/hr/kg
) 
Tmax(hr
) 
SN79-di-
HCl 
111.3 ±  
0.12 
7.8 ±  
0.7 
0.21 ±  
0.21 
10.1 ±  
1.3 
113.7 ±  
1.1 
0.13 ± 
0.11 
1.52 ± 
0.05 
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Figure 5.13 Mean plasma concentration time profile of SN79-di-HCl in fed state 
male Sprague dawley rats oral administration (20mg/kg) (n=6) 
Table 5.12 Mean plasma pharmacokinetic parameters of SN79-di-
hydrochloride after oral administration to fed state male Sprague 
dawley rats (20mg/kg) (n=6) 
AUC – area under the curve; T1/2 – plasma half life; Cmax – maximum plasma concentration; 
MRT – mean residence time; Vd – volume of distribution; CL – plasma clearance; Tmax – time 
of maximum plasma concentration.  
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5.7 In vitro GIT Permeation Studies 
The optimization of the bioavailability of drugs administered via the oral route is one of the most 
important aims for the pharmaceutical industry during the development phase of new products 
[301]. Bioavailability is characterized by both the amount of drug absorbed from the dosage 
form reaching the systemic circulation and the rate of this process. For the oral route, the 
quantity of drug reaching the systemic circulation is influenced by many factors. These include 
physicochemical interactions with the environment in the intestinal lumen, as well as biological 
interactions with the physiology and anatomy of the intestinal membrane, which either interfere 
or aid in the transport process [270]. For most drugs, the absorption from the gastrointestinal 
tract is mediated by passive diffusion from the lipid membrane.  
The absorption pattern of SN79-di-HCl was studied across the gastrointestinal tract. Various 
sections of the gut including duodenum, jejunum and ileum were used to determine the 
permeability of SN79. Mass transport across a barrier, can be caused by diffusion or migration. 
Permeability was calculated from the measured flux of diffusion and the concentration gradient. 
The permeation of SN79 from mucosal side to serosal (A-B) and from serosal to mucosal side 
(B-A) was studied (Table 5.13). Permeability of SN79-di-HCl from A-B across duodenum, 
jejunum and ileum was 2.53x10-6 cm/sec, 2.33x10-6 cm/sec and 2.47x10-6 cm/sec respectively. 
There was no significant difference in these values. Similarly, the permeability of SN79-di-HCl 
from B-A across duodenum, jejunum and ileum was 1.64x10-5 cm/sec, 1.73x10-5 cm/sec and 
1.61x10-5 cm/sec.  
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Section of 
GIT 
SN79-di-HCl   
(A-B) Papp x 10-6 cm/sec (B-A) Papp x 10-5 cm/sec 
(B-A)/(A-
B) 
  
Duodenum 2.53 1.64 0.65 
Jejunum 2.33 1.73 0.74 
Ileum 2.47 1.61 0.65 
 
 
5.8 In vitro Metabolic Stability 
The liver poses particular problems in constructing physiologically-based pharmacokinetic 
models since this organ is not only a distribution site for drugs/chemicals but frequently the 
major site of metabolism [302]. The importance of hepatic drug metabolism is substantial and 
also it is crucial to the success of the model that the in vitro data on the kinetics of metabolism be 
incorporated in a judicious manner. The key parameter in in vitro drug metabolism is intrinsic 
clearance (CLint), which is a pure measure of enzyme activity towards a substrate and is 
independent of other physiological determinants such as blood flow or drug binding within the 
matrix [302]. Apparent intrinsic clearance of SN79 was measured using rat liver microsomes. 
The determination of in vitro intrinsic clearance (Clint) for drug candidates in the early discovery 
stage is a common practice in pharmaceutical industry [269]. From toxicological and 
pharmacological points of view, it is desirable to design a “safer” drug that undergoes 
predictable metabolic inactivation or no metabolism [303]. The in vitro half life of SN79 when 
incubated in rat liver microsomes was found to be 0.25 hr, which is less than in vivo half life  
Table 5.13 Mean apparent permeability of SN79-di-HCL from 
mucosal to serosal (A-B) and from serosal to mucosal side (B-A) 
Papp – apparent permeability coefficient of SN79-di-HCl 
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Time (min) % SN79 Remaining  SEM 
0 100 0 
10 57.8 0.03 
15 46.1 0.02 
30 34.9 0.03 
45 25 0.09 
60 7.2 0.02 
90 1.2 0.02 
 
value, 1.36 hr after intravenous administration (Table 5.6).  The apparent intrinsic clearance 
derived from in vitro t1/2 value is 4.66 L/hr/kg. This value is higher than the in vivo clearance 
value, 0.18 L/Hr/kg after intravenous administration (Table 5.6). This might be attributed to the 
high protein binding nature of SN79-di-HCl. Owing to its high affinity for plasma proteins 
(Section 5.5), the compound maybe less available for metabolizing enzymes. The in vivo t1/2 
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Figure 5.14 Metabolic stability of SN79-di-HCl incubated in rat liver 
microsomes (n=3) 
SEM = standard deviation/mean 
Table 5.14 Metabolic stability of SN79-di-HCl incubated in 
rat liver microsomes (n=3) 
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(1.36 hr) is prolonged since larger drug-protein complex cannot easily penetrate the metabolizing 
organ, liver. SN79-di-HCl is considered metabolically unstable since less than 20% of the 
compound was remaining at sixty minutes [304].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
127 
 
CHAPTER VI: CONCLUSIONS 
With the advance of medicinal chemistry, many new tools have been developed to help discover 
better drugs faster. In pursuit of a selective sigma-2 receptor ligand, SN79 (6-acetyl-3-(4-(4-(4-
fluorophenyl) piperazin-1-yl) butyl) benzo[d] oxazol-2 (3H)-one) with a molecular weight of 
411.3 daltons was synthesized by Dr. Christopher R. McCurdy’s group from the Department of 
Medicinal Chemistry at the University of Mississippi. This compound was selected for further 
development as a potential lead candidate. Absorption, distribution, metabolism and excretion 
were determined as these processes play a critical role in selecting high quality hits and leads for 
drug discovery programs.  
Ultra performance liquid chromatography-mass spectrophotometry (UPLC-MS) was the analysis 
tool of choice throughout this dissertation. A simple, sensitive and accurate UPLC-MS method 
using single ion reaction mode was developed in rat plasma that is capable of rapid separation 
and selective identification of SN79 in rat plasma. The extraction procedure is simple and short, 
allowing sufficient sample-throughput to be applied to pharmacokinetic studies of SN79. The 
method was validated in accordance with FDA guidelines and was shown to be reproducible and 
accurate. The volume of injection was optimized to 10 µL, thereby making it beneficial 
considering the limitation of sample volumes obtained during pharmacokinetic studies. Thus, the 
method was successfully applied to in vivo studies conducted in rats.  
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As part of drug discovery and development, there is a need to better understand the 
physicochemical properties of SN79. Assays were performed to determine important 
physicochemical properties that influence oral absorption, membrane permeation and a host of 
other critical ADME processes. Log P and pKa values, solubility in aqueous and buffered media, 
influence of temperature and pH on stability were determined. Based on these results, it was 
concluded that SN79 is basic and lipophilic.  
Understanding the impact stability continues to have on drug discovery and development, a 
number of in vitro studies including stability testing in simulated gastric and intestinal fluids and 
metabolic stability in rat liver microsomes were also determined. SN79 emerged stable in the 
gastrointestinal fluids suggesting no precipitation or degradation occurs during absorption from 
the gut, while it exhibited susceptibility to metabolism such that less than 20% remained after 60 
minutes incubation with rat liver microsomes.  
With the required physiochemical data and knowledge of in vitro behavior, single dose 
pharmacokinetic studies were conducted in fasted state male Sprague Dawley rats. The average 
oral bioavailability was ~66% in fasted state subjects. A qualitative visual examination of the 
data indicated the presence of multiple peaks in the concentration-time profile of oral SN79-di-
HCl. Similar profiles were noticed for several compounds in literature and one of the plausible 
reason was the presence of absorption windows along the gastrointestinal tract. Consequently, a 
similar pharmacokinetic study was performed at the same dose in rats to establish the role of 
food on absorption of SN79-di-HCl from the gut. It was concluded that results from this study 
had no impact on the appearance of multiple peaks because the same phenomena was observed 
in the oral profile of fed state rats also. In support of this data, in vitro permeation in the 
gastrointestinal tract and plasma protein binding nature of SN79-di-HCl were also studied. The 
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results revealed that SN79-di-HCl is highly protein bound (~93%) with concentration 
dependence. The permeation of SN79-di-HCl along the three segments of the gut, duodenum, 
jejunum and ileum was found to be similar, thus, ruling out the possibility of presence of 
absorption windows for SN79 along GIT. 
In conclusion, a novel synthetic compound, SN79 was researched as part of drug discovery and 
development with different focuses. Despite low in vitro metabolic stability and high protein 
binding affinity, the compound did have good oral bioavailability and showed no severe acute 
toxicity response in rats at the doses administered, thereby paving way to take the compound for 
further investigations. Structural modifications to the chemical moiety might help improve the 
metabolic stability without compromising bioavailability. 
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CHAPTER VII: FUTURE STUDIES 
• The underlying cause for appearance of multiple peaks in oral concentration-time profile 
of SN79-di-HCl must be determined. Based on data published in literature, studies can be 
conducted to see if variable gastric emptying rates and intestinal flow rates has a role in 
inducing multiple peaks.  
• One major determinant of pharmacokinetics of SN79-di-HCl is its disposition in the 
brain. Since SN79 is a drug that acts on the central nervous system, it is imperative to 
establish the amount of compound that crosses the blood brain barrier. This can be 
achieved by harvesting the brain of the rat after termination of the pharmacokinetic study 
and analyzing it for the presence of SN79. 
• Drug efflux pumps such as P-glycoprotein and multidrug resistance proteins are known to 
influence the pharmacokinetics of drugs administered intravenously and orally. To 
ascertain whether or not these transporters have a bearing on the intestinal absorption and 
tissue distribution of SN79, pharmacokinetic studies can be performed in presence and 
absence of transporter inhibitors and compare the difference in oral bioavailabilities thus 
obtained.  
• For certain drugs, in vivo metabolites tend to have similar therapeutic response as the 
parent drug or in some cases, induce a toxic response. Hence, identification and 
quantitative determination of metabolites in rat urine might be helpful in understanding 
the pathways of metabolism, thereby mitigating any unwanted effects.
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Table A.1. Calibration curve of SN79-di-HCl for intraday accuracy and precision of SN79 
in rat plasma. 
 
 
 
 
 
 
 
Initial Conc (ng/mL) Area Response Conc (ng/mL) Accuracy RSD
346.0 0.0026 5.069 101.38
354.1 0.0025 4.935 98.71
355.3 0.0026 5.050 101.01
359.3 0.0026 5.005 100.10
357.0 0.0025 4.886 97.71
353.6 0.0024 4.696 93.93
1077 0.0077 14.95 99.6
1099 0.0078 15.16 101.0
1092 0.0076 14.74 98.2
1085 0.0076 14.92 99.50
1091 0.0079 15.40 102.65
1086 0.0077 15.09 100.6
14504 0.0976 190.4 95.22
15085 0.1019 198.8 99.4
14557 0.1039 202.7 101.36
14750 0.1028 200.7 100.34
15263 0.1061 207.1 103.57
14885 0.1032 201.4 100.7
230753 1.5233 2973 99.10
230937 1.6016 3126 104.2
229580 1.6188 3159 105.32
222925 1.5979 3119 103.95
228500 1.5662 3057 101.89
225442 1.6183 3158 105.28
0.03
0.02
0.03
0.02
5
15
200
3000
 
       RSD = standard deviation/mean accuracy = (conc/spiked conc)*100 
Conc (ng/ml) Area 
5 390 
10 766 
50 4008 
100 7703 
500 40026 
1000 72193 
5000 401532 
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Table A.2. Calibration curve of SN79-di-HCl for intraday accuracy and precision of SN79 
in rat plasma after 4 hr. 
 
 
 
 
 
 
 
 
Initial Conc (ng/mL) Area Response Conc (ng/mL) Accuracy RSD
345.6 0.0025 4.882 97.63
335.7 0.0024 4.748 94.96
324.2 0.0025 4.885 97.71
333.8 0.0024 4.733 94.66
332.4 0.0025 4.907 98.15
337.6 0.0024 4.707 94.13
1165 0.0084 16.32 108.8
1236 0.0080 15.70 104.6
1030 0.0077 15.04 100.3
1019 0.0073 14.31 95.38
1099 0.0075 14.67 97.80
1125 0.0081 15.83 105.6
13705 0.0980 191.2 95.59
13795 0.1043 203.6 101.8
13699 0.1016 198.3 99.15
13703 0.1020 199.1 99.56
13599 0.1006 196.3 98.14
13741 0.1055 206.0 103.0
189435 1.4387 2808 93.60
209750 1.5591 3043 101.4
194008 1.4735 2876 95.86
200329 1.4836 2896 96.52
185615 1.4076 2747 91.57
185121 1.4081 2748 91.60
0.02
0.05
0.03
0.04
5
15
200
3000
RSD = standard deviation/mean accuracy = (conc/spiked conc)*100 
Conc (ng/ml) Area 
5 417 
10 752 
50 3825 
100 7815 
500 38293 
1000 74235 
5000 425320 
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Table A.3. Calibration curve of SN79-di-HCl for intraday accuracy and precision of SN79 
in rat plasma after 6 hr. 
 
 
 
 
 
 
 
 
Initial Conc (ng/mL) Area Response Conc (ng/mL) Accuracy RSD
257.8 0.0019 4.157 83.14
255.9 0.0019 4.201 84.03
258.8 0.0019 4.336 86.72
242.2 0.0018 4.031 80.62
253.8 0.0018 4.092 81.84
222.9 0.0016 3.603 72.06
876 0.0063 14.24 94.9
890 0.0063 14.20 94.7
892 0.0064 14.29 95.3
880 0.0063 14.11 94.06
885 0.0065 14.59 97.28
881 0.0064 14.26 95.0
12724 0.0911 204.5 102.27
12191 0.0877 196.8 98.4
11911 0.0874 196.2 98.08
12327 0.0881 197.7 98.87
11756 0.0894 200.6 100.30
12777 0.0913 204.8 102.4
188208 1.3563 3044 101.46
182920 1.3488 3027 100.9
189935 1.3743 3084 102.80
187775 1.3578 3047 101.57
189942 1.3743 3084 102.81
187121 1.3420 3012 100.39
0.06
0.01
0.02
0.01
5
15
200
3000
 
         RSD = standard deviation/mean accuracy = (conc/spiked conc)*100 
Conc (ng/ml) Area 
5 350 
10 730 
50 3429 
100 7329 
500 33772 
1000 77708 
5000 308510 
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Table A.4. Calibration curve of SN79-di-HCl for intraday accuracy and precision of SN79 
in rat plasma after 8 hr. 
 
 
 
 
 
 
 
Initial Conc (ng/mL) Area Response Conc (ng/mL) Accuracy RSD
334.7 0.0025 5.037 100.73
324.9 0.0024 4.914 98.28
322.9 0.0024 4.982 99.64
314.1 0.0024 4.815 96.30
319.2 0.0024 4.839 96.79
320.9 0.0025 5.043 100.86
1089 0.0080 16.39 109.2
1098 0.0079 16.16 107.7
1083 0.0078 15.88 105.9
1055 0.0076 15.61 104.05
1052 0.0079 16.24 108.25
1067 0.0076 15.64 104.3
13585 0.0976 199.7 99.86
14282 0.1019 208.5 104.2
13569 0.0975 199.5 99.76
13430 0.0962 196.8 98.41
13278 0.0949 194.2 97.11
13811 0.1018 208.3 104.2
204942 1.4720 3011 100.38
202909 1.4777 3023 100.8
202276 1.5061 3081 102.71
200055 1.5015 3072 102.39
206572 1.4813 3030 101.01
208576 1.4949 3058 101.95
0.02
0.02
0.03
0.01
5
15
200
3000
 
        RSD = standard deviation/mean accuracy = (conc/spiked conc)*100 
Conc (ng/ml) Area 
5 371 
10 688 
50 3764 
100 6895 
500 35483 
1000 66826 
5000 339499 
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Table A.5. Calibration curve of SN79-di-HCl for interday accuracy and precision on day 
one. 
 
 
 
 
 
 
 
 
Initial Conc (ng/mL) Area Response Conc (ng/mL) Accuracy RSD
354.2 0.0025 5.046 100.93
349.3 0.0025 4.987 99.74
355.9 0.0025 5.053 101.07
334.8 0.0024 4.785 95.70
349.1 0.0025 4.987 99.73
342.7 0.0025 4.880 97.61
973 0.0071 14.17 94.5
954 0.0069 13.64 90.9
968 0.0070 13.93 92.9
952 0.0073 14.58 97.22
939 0.0071 14.19 94.59
959 0.0069 13.74 91.6
14255 0.1102 218.9 109.47
13940 0.1004 199.4 99.7
13828 0.1015 201.8 100.88
13397 0.1010 200.7 100.37
13685 0.0982 195.1 97.56
13244 0.1024 203.4 101.7
200970 1.4494 2880 96.01
211646 1.4521 2886 96.2
209203 1.5737 3127 104.25
210913 1.6266 3233 107.75
216475 1.4773 2936 97.86
211500 1.4967 2974 99.14
0.02
0.02
0.04
0.05
5
15
200
3000
 
         RSD = standard deviation/mean accuracy = (conc/spiked conc)*100 
Conc (ng/ml) Area 
5 377 
10 604 
50 3720 
100 6073 
500 35143 
1000 65817 
5000 388304 
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Table A.6. Calibration curve of SN79-di-HCl for interday accuracy and precision on day 
two. 
 
 
 
 
 
 
 
Initial Conc (ng/mL) Area Response Conc (ng/mL) Accuracy RSD
406.1 0.0030 5.098 102.0
413.1 0.0031 5.339 106.8
410.0 0.0031 5.283 105.7
411.4 0.0030 5.154 103.1
413.3 0.0031 5.229 104.6
405.9 0.0030 5.061 101.2
1163 0.0083 14.14 94.29
1164 0.0085 14.38 95.87
1185 0.0085 14.40 96.01
1121 0.0086 14.60 97.34
1190 0.0087 14.71 98.10
1101 0.0084 14.26 95.07
17126 0.1231 209.1 104.5
15200 0.1132 192.3 96.16
16860 0.1233 209.6 104.8
17083 0.1230 208.9 104.5
15356 0.1144 194.4 97.21
15550 0.1138 193.3 96.63
245492 1.8604 3161 105.4
242173 1.8021 3062 102.1
248652 1.7821 3028 100.9
247487 1.8740 3184 106.1
242558 1.7702 3007 100.2
237068 1.8029 3063 102.1
0.02
0.01
0.04
0.02
5
15
200
3000
 
         RSD = standard deviation/mean accuracy = (conc/spiked conc)*100 
Conc (ng/ml) Area 
5 429 
10 810 
50 4653 
100 10510 
500 40843 
1000 79450 
5000 396903 
174 
 
Table A.7. Calibration curve of SN79-di-HCl for interday accuracy and precision on day 
three. 
 
 
 
 
 
 
 
Initial Conc (ng/mL) Area Response Conc (ng/mL) Accuracy RSD
336.3 0.0025 5.053 101.1
324.1 0.0025 4.989 99.77
345.3 0.0025 5.034 100.7
318.9 0.0025 4.906 98.12
347.0 0.0026 5.237 104.7
343.6 0.0025 5.022 100.4
1078 0.0082 16.51 110.1
1000 0.0076 15.22 101.5
1042 0.0075 14.94 99.57
1025 0.0073 14.66 97.74
1011 0.0073 14.63 97.51
1016 0.0073 14.58 97.21
13306 0.1019 203.9 101.9
12785 0.0983 196.7 98.37
12857 0.0988 197.7 98.87
13050 0.1000 200.2 100.1
13263 0.0991 198.4 99.20
13285 0.0990 198.1 99.05
200753 1.4818 2966 98.86
210937 1.5719 3146 104.9
200580 1.4346 2871 95.72
210325 1.5076 3018 100.6
210600 1.4947 2992 99.73
208642 1.4977 2998 99.93
0.02
0.05
0.01
0.03
5
15
200
3000
 
        RSD = standard deviation/mean accuracy = (conc/spiked conc)*100 
Conc (ng/ml) Area 
5 390 
10 766 
50 4008 
100 7703 
500 40026 
1000 72193 
5000 341532 
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Table A.8. Calibration curve of SN79-di-HCl for short term freeze thaw stability in rat 
plasma. 
 
 
 
 
 
 
 
 
Short-term stability of SN79-di-HCl after 4 hours of incubation in rat plasma (n=3) 
 
 
Initial Conc (ng/mL) Area Response Conc (ng/mL) Accuracy
751.8 0.0057 4.399 87.97
770.3 0.0057 4.454 89.08
770.9 0.0058 4.654 93.08
1421 0.0105 13.96 93.05
1412 0.0102 13.32 88.81
1441 0.0107 14.49 96.57
13554 0.0999 192.8 96.38
13776 0.0992 191.5 95.74
13916 0.1011 195.2 97.60
205705 1.5137 3020 100.7
197986 1.5767 3146 104.9
199359 1.4726 2938 97.94
5
15
200
3000
 
     RSD = standard deviation/mean accuracy = (conc/spiked conc)*100 
 
 
Conc (ng/ml) Area 
5 390 
10 766 
50 4008 
100 7703 
500 40026 
1000 72193 
5000 341532 
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Short-term stability of SN79-di-HCl after 6 hours of incubation in rat plasma (n=3) 
 
Initial Conc (ng/mL) Area Response Conc (ng/mL) Accuracy RSD
763.2 0.0056 4.120 82.39
772.7 0.0058 4.626 92.52
775.5 0.0056 4.213 84.25
1389 0.0101 13.16 87.70
1381 0.0101 13.12 87.46
1385 0.0102 13.49 89.93
11937 0.0907 174.4 87.20
11565 0.0843 161.6 80.78
11834 0.0872 167.3 83.66
168592 1.1990 2391 79.7
169405 1.2131 2419 80.6
167470 1.2039 2401 80.03
5
15
200
3000
6.24
1.54
3.83
0.60
 
RSD = standard deviation/mean accuracy = (conc/spiked conc)*100 
 
Short-term stability of SN79-di-HCl after 8 hours of incubation in rat plasma (n=3) 
Initial Conc (ng/mL) Area Response Conc (ng/mL) Accuracy RSD
747.0 0.0056 4.150 83.00
732.7 0.0056 4.183 83.66
752.7 0.0055 4.059 81.18
1357 0.0100 13.10 87.33
1337 0.0096 12.15 81.01
1326 0.0097 12.42 82.83
11751 0.0865 166.0 83.01
11904 0.0905 173.9 86.96
11707 0.0839 160.9 80.43
165908 1.2317 2456 81.88
163912 1.1948 2383 79.42
5
15
200
3000
1.55
3.89
3.93
2.16
 
RSD = standard deviation/mean accuracy = (conc/spiked conc)*100 
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Table A.9. Calibration curve of SN79-di-HCl for freeze thaw cycle in rat plasma. 
 
 
 
 
 
 
 
 
 
Stability of SN79-di-HCl in rat plasma after three freeze thaw cycles in rat plasma (n=3) 
 
 
Initial Conc (ng/mL) Area Response Conc (ng/mL) Accuracy RSD
245.7 0.0018 5.175 103.5
246.0 0.0018 5.037 100.7
247.5 0.0018 5.139 102.8
758.6 0.0054 15.21 101.4
755.7 0.0055 15.53 103.5
740.6 0.0056 15.65 104.3
9423 0.0705 197.6 98.81
9588 0.0690 193.3 96.63
9481 0.0708 198.5 99.26
137081 0.9940 2786 92.86
135077 1.0369 2906 96.87
132086 1.0113 2834 94.48
2.133000
5
15
200
1.39
1.48
1.43
 
       RSD = standard deviation/mean accuracy = (conc/spiked conc)*100 
 
 
Conc (ng/ml) Area 
5 251 
10 474 
50 2572 
100 4545 
500 26544 
1000 46427 
5000 239845 
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Table A.10. Calibration curve of SN79-di-HCl for 30 days stability in rat plasma. 
 
 
 
 
 
 
 
Stability of SN79-di-HCl in rat plasma after 30 days (n=3) 
 
Initial Conc (ng/mL) Area Response Conc (ng/mL) Accuracy RSD
390.2 0.0029 4.729 94.58
384.8 0.0029 4.632 92.64
380.1 0.0028 4.529 90.58
1111 0.0084 13.59 90.58
1132 0.0087 14.08 93.85
1098 0.0083 13.54 90.29
15741 0.1188 193.0 96.48
15517 0.1145 186.0 93.01
14376 0.1090 177.0 88.52
203441 1.4777 2400 80.02
230399 1.7375 2823 94.08
234513 1.6797 2729 90.95
0.943000
5
15
200
1.73
3.26
4.31
 
        RSD = standard deviation/mean accuracy = (conc/spiked conc)*100 
 
 
Conc (ng/ml) Area 
5 436 
10 974 
50 4694 
100 9095 
500 41304 
1000 83955 
5000 423645 
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Table.B.1. pKa determination of SN79-di-HCl. Data presented as volume of HCl 
added vs pH of the resulting SN79 solution. (n=2) 
Volume of NaOH added (in µL) pH
100 6.16
200 6.69
300 7.26
400 8.2
500 8.51
600 8.79
700 9.18
800 9.15
900 9.35
1000 9.49
1100 9.6
1200 9.65
1300 9.7
1400 9.77
1500 9.82
Volume of HCl added (in µL) pH
100 9.52
200 9.26
300 8.19
400 7.52
500 7.23
600 7.05
700 6.89
800 6.73
900 6.59
1000 6.43
1100 6.24
1200 6.02
1300 5.65
1400 5.07
1500 4.62
1600 4.37
1700 4.22
1800 4.1
1900 4.01
2000 3.93
2100 3.87
2200 3.81
2300 3.77
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Volume of NaOH added (in µL) pH
100 6.37
200 7.28
300 8.33
400 8.86
500 9.14
600 9.12
700 9.17
800 9.28
900 9.33
1000 9.38
Volume of HCl added (in µL) pH
100 9.16
200 8.68
300 7.72
400 7.29
500 6.92
600 6.72
700 6.48
800 6.29
900 5.99
1000 5.61
1100 5.11
1200 4.69
1300 4.44
1400 4.29
1500 4.18
1600 4.08
1700 4.01
1800 3.94
1900 3.88
2000 3.84
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Table B.2. Calibration curve of SN79-di-HCl for solubility studies. 
Conc (ng/mL) Area 
5 399 
10 759 
25 2047 
50 4209 
100 7884 
200 15938 
500 38451 
1000 72987 
3000 218359 
5000 407577 
 
pH dependant solubility of SN79-di-HCl in buffers prepared as per the USP guidelines 
(n=3). 
pH Area Conc (ng/mL) Dilution Factor Conc (ng/mL) Conc (mg/mL) Average SEM
93299 1196 20000 23914866 23.9
91526 1173 20000 23468879 23.5
94319 1209 20000 24171485 24.2
101434 1298 20000 25961263 26.0
106970 1368 20000 27353792 27.4
102468 1311 20000 26221356 26.2
110469 1412 20000 28233933 28.2
111200 1421 20000 28417809 28.4
116382 1486 20000 29721293 29.7
107548 1375 20000 27499182 27.5
99172 1270 20000 25392278 25.4
105146 1345 20000 26894982 26.9
80639 1037 20000 20730474 20.7
82923 1065 20000 21304993 21.3
81737 1050 20000 21006666 21.0
0.01
0.03
0.03
0.04
0.01
1.2
3
5
7.4
9
23.9
26.5
28.8
26.6
21.0
SEM = standard deviation/average 
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Table B.3. Stability of SN79-di-HCl in stimulated gastric fluid (pH = 1.2) prepared as per 
USP guidelines (n=3) 
 
Time 
(min) Area 
Conc 
(ng/mL) 
Conc 
(µg/mL) 
Mean Conc 
(µg/mL) SEM RD 
0 
910213 4520.6 4.52 
4.46 0.04 0 881696 4379.1 4.38 
899613 4468.0 4.47 
60 
904972 4494.6 4.49 
4.46 0.04 -0.04 881715 4379.2 4.38 
906013 4499.8 4.50 
 
 
Table B.4. Stability of SN79-di-HCl in stimulated intestinal fluid (pH = 1.2) prepared as per 
USP guidelines (n=2) 
Time 
(min) Area 
Conc 
(ng/mL) 
Conc 
(µg/mL) 
Mean Conc 
(µg/mL) SEM RD 
0 923610 4587.1 4.59 4.56 0.03 0 910800 4523.6 4.52 
60 921231 4575.3 4.58 4.57 0.01 -0.25 917681 4557.7 4.56 
120 933605 4636.7 4.64 4.60 0.04 -0.96 918517 4561.9 4.56 
180 916136 4550.0 4.55 4.55 0.003 0.19 914804 4543.4 4.54 
 
 
 
 
 
 
 
 
SEM = standard deviation/average; RD = [(initial conc-conc at time t)/initial conc]*100 
SEM = standard deviation/average; RD = [(initial conc-conc at time t)/initial conc]*100 
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Table B.5. Calibration curve of SN79-di-HCl for protein binding study 
Conc(ng/mL) Drug Area 
5 1001 
10 2802 
25 4907 
50 8941 
100 18231 
200 37123 
500 93934 
1000 208675 
3000 608090 
5000 1009967 
 
 
Concentration dependant protein binding study of SN79-di-HCl incubated in rat plasma 
(n=3) 
Incubated Conc 
(ug/mL) Area Concug/mL 
Mean Conc 
(ug/mL) Fu Fu % SEM 
0.5 
2895 0.019 
0.019 0.039 3.90 0.006 2903 0.019 
2938 0.019 
1 
7593 0.042 
0.043 0.045 4.53 0.029 8060 0.044 
8006 0.044 
5 
50288 0.253 
0.257 0.054 5.42 0.030 50325 0.253 
52972 0.266 
10 
153593 0.763 
0.761 0.082 8.24 0.002 153060 0.760 
153006 0.760 
 
 
 
SEM = standard deviation/average; RD = [(initial conc-conc at time t)/initial conc]*100 
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Table B.6. Calibration curve for determination of SN79 content in rat plasma samples after 
administration of SN79-di-HCl to fasted state male Sprague Dawley rats 
Conc 
(ng/mL) Ratio 
5 0.0034 
10 0.0058 
25 0.0153 
50 0.0304 
100 0.0573 
250 0.1250 
300 0.1563 
500 0.2274 
1000 0.5120 
2500 1.2387 
3000 1.4221 
5000 2.1916 
 
Determination of SN79 content in rat plasma samples after IV administration of SN79-di-
HCl to fasted state Sprague Dawley rats (5mg/kg) - Rat 1 
Time (min) Drug Area IS Area Ratio Conc (ng/mL)
1 75998 124576 0.61 1392
3 51497 106189 0.48 1106
5 48688 115329 0.42 963
10 26641 109322 0.24 556
15 21136 122032 0.17 395
20 19460 114843 0.17 387
30 13289 119084 0.11 255
45 12097 114319 0.11 241
60 11388 118356 0.10 219
90 6699 126714 0.05 121
120 2866 136586 0.02 48
150 2176 137453 0.02 36
180 1584 127064 0.01 28
240 1473 130338 0.01 26
300 1189 117070 0.01 23
360 993 141152 0.01 16
420 895 131568 0.01 16
480 850 133052 0.01 15
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Determination of SN79 content in rat plasma samples after IV administration of SN79-di-
HCl to fasted state Sprague Dawley rats (5mg/kg) - Rat 2 
 
Time (min) Drug Area IS Area Ratio Conc (ng/mL)
1 91793 118336 0.78 1769
3 71257 141920 0.50 1145
5 46861 125929 0.37 849
10 43100 139799 0.31 703
15 31178 140848 0.22 505
20 24993 138601 0.18 411
30 19980 126571 0.16 360
60 18854 126424 0.15 340
90 12093 134638 0.09 205
120 10218 74464 0.14 313
150 2787 114096 0.02 56
180 1925 132230 0.01 33
240 1453 132138 0.01 25
300 1438 138531 0.01 24
360 1057 136133 0.01 18
420 963 141834 0.01 15
480 799 132122 0.01 14
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Determination of SN79 content in rat plasma samples after IV administration of SN79-di-
HCl to fasted state Sprague Dawley rats (5mg/kg) - Rat 3 
 
Time (min) Drug Area IS Area Ratio Conc (ng/mL)
1 73645 148165 0.50 1134
3 44712 152349 0.29 669
5 36840 145382 0.25 578
10 36662 131785 0.28 635
15 29201 151034 0.19 441
20 25853 154501 0.17 382
30 16762 151104 0.11 253
45 15286 129051 0.12 270
60 11509 151502 0.08 173
90 7498 129894 0.06 132
120 4959 127697 0.04 89
150 3353 141429 0.02 54
180 2592 166453 0.02 36
240 1905 131674 0.01 33
300 1541 136474 0.01 26
360 1403 141500 0.01 23
420 923 152985 0.01 14
480 733 157022 0.005 11
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Determination of SN79 content in rat plasma samples after IV administration of SN79-di-
HCl to fasted state Sprague Dawley rats (5mg/kg) - Rat 4 
 
Time (min) Drug Area IS Area Ratio Conc (ng/mL)
1 82258 142829 0.58 1314
3 68813 125980 0.55 1246
10 33270 119369 0.28 636
15 23660 138029 0.17 391
20 18636 137527 0.14 309
30 15472 134626 0.11 262
45 15253 150298 0.10 231
60 6805 158665 0.04 98
90 5511 129904 0.04 97
120 4159 135634 0.03 70
150 1819 150266 0.01 28
180 1654 131344 0.01 29
240 938 141375 0.01 15
300 879 137283 0.01 15
360 710 112066 0.01 14
420 483 129848 0.004 8
480 412 126564 0.004 10
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Determination of SN79 content in rat plasma samples after IV administration of SN79-di-
HCl to fasted state Sprague Dawley rats (5mg/kg) - Rat 5 
 
Time (min) Drug Area IS Area Ratio Conc (ng/mL)
1 67201 138599 0.48 1106
3 44276 132513 0.33 762
5 35969 130333 0.28 630
10 26858 134592 0.20 455
15 17950 124994 0.14 328
20 16268 130554 0.12 284
30 12070 130196 0.09 211
45 11754 130542 0.09 205
60 7530 151003 0.05 114
90 6248 127518 0.05 112
120 3113 132660 0.02 54
150 2947 147527 0.02 46
180 2708 133342 0.02 46
240 1222 125014 0.01 22
300 974 125751 0.01 18
420 589 150914 0.004 9
480 409 118934 0.003 8
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Determination of SN79 content in rat plasma samples after oral administration of SN79-di-
HCl to fasted state Sprague Dawley rats (20mg/kg) - Rat 1 
Time (min) Drug Area IS Area Ratio Conc (ng/mL)
15 11170 168336 0.07 151
30 13208 122661 0.14 325
45 9042 179422 0.09 212
60 7543 179231 0.08 177
90 12756 121404 0.11 240
120 11783 125972 0.14 313
150 9781 159550 0.10 234
180 8165 129293 0.09 202
240 9445 126827 0.11 248
300 4504 123754 0.05 123
360 6228 148330 0.06 144
420 5600 148747 0.06 129
480 7120 105882 0.07 153
540 7386 106590 0.07 158
600 4612 102549 0.04 103
660 2599 145138 0.03 62
720 969 174742 0.01 30
1440 388 112335 0.35 18
2160 101 126473 0.80 8
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Determination of SN79 content in rat plasma samples after oral administration of SN79-di-
HCl to fasted state Sprague Dawley rats (20mg/kg) - Rat 2 
Time (min) Drug Area IS Area Ratio Conc (ng/mL)
15 7945 111727 0.07 162
30 13616 117916 0.12 278
45 8899 119460 0.07 170
60 8968 123543 0.07 166
90 10631 113522 0.09 214
120 10638 120228 0.09 202
150 15245 123068 0.12 283
180 12365 121316 0.10 232
240 12273 126015 0.10 222
300 4640 164130 0.07 165
360 5483 158424 0.09 214
420 15756 159836 0.26 601
480 5160 163703 0.08 185
540 2187 160144 0.04 83
600 2146 167955 0.03 72
660 1001 147531 0.02 48
720 1085 157401 0.02 43
1440 263 168206 0.004 13
2160 349 162403 0.01 9
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Determination of SN79 content in rat plasma samples after oral administration of SN79-di-
HCl to fasted state Sprague Dawley rats (20mg/kg) - Rat 3 
Time (min) Drug Area IS Area Ratio Conc (ng/mL)
15 6283 110268 0.06 130
30 6658 116122 0.06 131
45 5648 109967 0.05 117
60 6145 102198 0.06 137
90 8272 115461 0.07 163
120 8377 101372 0.08 188
150 6602 106108 0.06 142
180 7717 134616 0.06 131
240 8037 132423 0.06 138
300 6353 118994 0.05 122
360 6286 120660 0.05 119
420 5339 119752 0.04 102
480 4803 119105 0.04 92
540 5880 140455 0.04 96
600 2584 127128 0.02 46
660 1485 117351 0.01 29
720 1373 115485 0.01 27
1440 887 116791 0.01 17
2160 218 132764 0.002 4
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Determination of SN79 content in rat plasma samples after oral administration of SN79-di-
HCl to fasted state Sprague Dawley rats (20mg/kg) - Rat 4 
Time (min) Drug Area IS Area Ratio Conc (ng/mL)
15 10362 139895 0.07 169
30 10626 120782 0.09 201
45 8997 138006 0.07 149
60 7855 137838 0.06 130
90 11400 129154 0.09 201
120 7668 115219 0.07 152
150 8045 123779 0.06 148
180 8466 116968 0.07 165
240 7542 126376 0.06 136
300 5536 129267 0.04 98
360 5583 126820 0.04 100
420 3304 121492 0.03 62
480 2572 127154 0.02 46
540 1413 122696 0.01 26
600 1176 133420 0.01 20
660 617 110108 0.01 13
720 924 107360 0.01 20
1440 550 116177 0.005 11
2160 663 102927 0.01 15
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Determination of SN79 content in rat plasma samples after oral administration of SN79-di-
HCl to fasted state Sprague Dawley rats (20mg/kg) - Rat 5 
 
Time (min) Drug Area IS Area Ratio Conc (ng/mL)
15 6745 132863 0.05 116
30 7860 132186 0.09 194
45 8267 126980 0.07 149
60 10567 130359 0.08 185
90 10795 120260 0.09 205
120 7369 140641 0.05 120
150 10778 133202 0.08 185
180 6909 108586 0.06 145
240 7291 129670 0.06 128
300 7015 113727 0.06 141
360 6092 111921 0.05 124
420 3304 126061 0.03 60
480 1713 122260 0.01 32
540 1154 140177 0.01 19
600 1493 139624 0.01 24
660 1186 122942 0.01 22
720 1424 129818 0.01 25
1440 1167 122623 0.01 22
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Table B.7. Calibration curve for determination of SN79 content in rat plasma samples after 
administration of SN79-di-HCl to fed state male Sprague Dawley rats 
 
Conc(ng/mL) Ratio
5 0.0038
10 0.0083
25 0.0183
50 0.0402
100 0.0081
200 0.0185
500 0.3733
1000 0.8810
3000 2.3564
5000 3.8771
 
Determination of SN79 content in rat plasma samples after intravenous administration of 
SN79-di-HCl to fed state Sprague Dawley rats (5mg/kg) - Rat 1 
Time (min) Drug Area IS Area Ratio Conc (ng/mL)
1 43339 158110 0.75 1500
3 24264 152799 0.46 927
5 20563 147702 0.43 870
10 14425 167046 0.30 439
15 12968 143766 0.22 601
20 9225 164889 0.16 293
30 8676 155032 0.14 324
45 6134 164574 0.09 198
60 5121 174527 0.07 146
90 4812 173380 0.07 139
120 1566 169648 0.02 53
150 928 165263 0.01 37
180 806 164798 0.01 33
240 541 171535 0.01 23
300 421 176166 0.01 19
360 409 160134 0.01 22
420 354 146410 0.01 23
480 316 161264 0.01 19
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Determination of SN79 content in rat plasma samples after intravenous administration of 
SN79-di-HCl to fed state Sprague Dawley rats (5mg/kg) - Rat 2 
 
Time (min) Drug Area IS Area Ratio Conc (ng/mL)
1 66005 159793 1.10 2216
3 30912 164288 0.52 970
5 29143 156424 0.48 1041
10 17060 153764 0.34 643
15 14343 142067 0.32 690
20 10647 166302 0.21 329
30 9063 142407 0.16 436
45 7739 163907 0.12 250
60 5967 159871 0.10 208
90 3163 162180 0.05 110
120 2131 168345 0.03 71
150 1693 164054 0.03 61
240 871 164618 0.01 35
300 504 158543 0.01 25
360 437 148586 0.01 26
420 360 145083 0.01 24
480 358 126394 0.01 35
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Determination of SN79 content in rat plasma samples after intravenous administration of 
SN79-di-HCl to fed state Sprague Dawley rats (5mg/kg) - Rat 3 
 
Time (min) Drug Area IS Area Ratio Conc (ng/mL)
1 46557 152767 0.88 1773
3 22014 148991 0.45 907
5 16599 151282 0.32 656
10 14106 151360 0.27 557
15 12468 157063 0.22 445
20 9842 161112 0.16 330
30 8270 160710 0.14 281
45 6353 162173 0.10 213
60 4524 167407 0.07 142
90 2667 166868 0.04 88
120 1692 172428 0.02 55
150 1393 167452 0.02 49
180 758 164265 0.01 32
240 725 168338 0.01 29
300 708 158654 0.01 32
360 578 158874 0.01 28
420 574 171860 0.01 24
480 522 155650 0.01 27
 
 
 
  
198 
 
Determination of SN79 content in rat plasma samples after intravenous administration of 
SN79-di-HCl to fed state Sprague Dawley rats (5mg/kg) - Rat 4 
 
Time (min) Drug Area IS Area Ratio Conc (ng/mL)
1 44576 175195 2.52 1194
3 32804 163198 0.59 1046
5 21584 160235 0.52 725
10 16238 165306 0.36 505
15 11729 153607 0.28 446
20 10428 137631 0.25 562
30 8393 164635 0.22 268
45 5062 151056 0.13 206
60 4482 146237 0.10 202
90 2595 166526 0.10 86
120 1669 161874 0.04 62
150 1489 154194 0.03 63
180 991 135473 0.03 64
240 747 151864 0.03 37
300 674 152931 0.01 34
360 627 144830 0.01 36
420 570 163851 0.01 26
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Determination of SN79 content in rat plasma samples after intravenous administration of 
SN79-di-HCl to fed state Sprague Dawley rats (5mg/kg) - Rat 5 
 
Time (min) Drug Area IS Area Ratio Conc (ng/mL)
1 55209 157246 0.96 1937
3 38427 162828 0.61 1231
5 35748 168213 0.52 1056
10 23248 160595 0.38 776
15 17684 164529 0.27 556
20 13568 163330 0.21 437
30 9396 150126 0.19 383
45 7366 160888 0.12 250
60 4653 146934 0.10 206
90 792 129595 0.03 62
120 303 128476 0.01 29
150 270 123314 0.01 31
180 264 126690 0.01 28
300 225 127371 0.01 25
360 193 125473 0.01 23
420 139 123615 0.01 20
480 123 131751 0.004 16
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Determination of SN79 content in rat plasma samples after intravenous administration of 
SN79-di-HCl to fed state Sprague Dawley rats (5mg/kg) - Rat 6 
 
 
 
 
  
Time (min) Drug Area IS Area Ratio Conc (ng/mL)
1 18022 130859 0.58 1176
3 16258 135051 0.46 936
5 10590 132425 0.33 661
10 9244 135331 0.26 531
15 7100 138814 0.19 374
20 4139 123066 0.18 367
30 3321 117474 0.18 388
45 2389 134257 0.07 148
60 1220 131546 0.04 86
90 1195 146350 0.03 60
120 568 124626 0.02 54
150 544 135586 0.02 39
180 333 135516 0.01 27
240 252 137166 0.01 22
360 221 140913 0.01 19
420 166 141801 0.004 16
480 102 133439 0.003 14
201 
 
Determination of SN79 content in rat plasma samples after oral administration of SN79-di-
HCl to fed state Sprague Dawley rats (20mg/kg) - Rat 1 
 
Time (min) Drug Area IS Area Ratio Conc (ng/mL)
30 4261 139700 0.11 223
45 4763 144014 0.11 225
60 3403 137567 0.09 189
90 5103 142425 0.12 249
120 5511 144411 0.12 256
150 3929 132831 0.12 248
180 4455 147292 0.09 197
240 1573 132810 0.05 104
300 1307 136569 0.04 80
360 1124 131039 0.04 81
480 2933 122452 0.13 269
540 1725 136968 0.05 101
600 1086 137226 0.03 67
660 590 143913 0.01 35
720 476 132127 0.01 38
2160 106 143213 0.002 13
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Determination of SN79 content in rat plasma samples after oral administration of SN79-di-
HCl to fed state Sprague Dawley rats (20mg/kg) - Rat 2 
 
Time (min) Drug Area IS Area Ratio Conc (ng/mL)
15 1700 134232 0.05 108
30 3076 145118 0.07 145
45 2895 142816 0.07 143
60 2553 141703 0.06 131
90 3042 148035 0.06 135
120 3778 147199 0.08 168
150 3369 142593 0.08 166
180 3287 141176 0.08 168
240 3277 147877 0.07 145
300 2651 139518 0.07 142
360 3018 140274 0.07 158
420 2041 136344 0.06 121
480 2291 139365 0.06 125
540 3017 149166 0.06 131
600 1009 141986 0.02 56
660 5449 137323 0.15 300
720 849 127853 0.03 69
1440 527 142230 0.01 33
2160 96 138933 0.002 13
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Determination of SN79 content in rat plasma samples after oral administration of SN79-di-
HCl to fed state Sprague Dawley rats (20mg/kg) - Rat 3 
Time (min) Drug Area IS Area Ratio Conc (ng/mL)
15 2617 129324 0.08 187
30 3514 148827 0.09 152
45 3971 156864 0.07 148
60 2067 131509 0.08 139
90 2272 135021 0.13 138
120 3370 143364 0.12 164
150 3507 146862 0.10 158
180 1528 129719 0.10 111
240 1195 131469 0.07 84
300 1185 130963 0.08 85
360 2029 137943 0.08 115
420 1862 148453 0.09 85
480 3495 148446 0.05 152
540 2489 141537 0.04 128
600 1015 136274 0.02 64
660 503 129297 0.01 43
720 418 129302 0.01 37
1440 454 117889 0.003 23
2160 167 143985 0.001 16
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Determination of SN79 content in rat plasma samples after oral administration of SN79-di-
HCl to fed state Sprague Dawley rats (20mg/kg) - Rat 4 
 
Time (min) Drug Area IS Area Ratio Conc (ng/mL)
15 2699 134942 0.08 163
30 4505 151640 0.09 183
45 2302 133656 0.07 145
60 3535 147554 0.07 157
90 3895 151340 0.08 160
120 1595 125984 0.06 131
150 694 123380 0.03 68
180 543 122700 0.02 56
240 1049 125434 0.04 91
300 1429 128175 0.05 110
360 1632 131115 0.05 113
420 2528 128741 0.09 184
480 1285 131016 0.04 91
540 571 123495 0.02 57
600 462 125451 0.02 44
660 405 130471 0.01 35
720 408 131304 0.01 34
1440 241 131914 0.01 23
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Determination of SN79 content in rat plasma samples after oral administration of SN79-di-
HCl to fed state Sprague Dawley rats (20mg/kg) - Rat 5 
 
Time (min) Drug Area IS Area Ratio Conc (ng/mL)
15 2699 134942 0.08 163
30 4505 151640 0.09 183
45 2302 133656 0.07 145
60 3535 147554 0.07 157
90 3895 151340 0.08 160
120 1595 125984 0.06 131
150 694 123380 0.03 68
180 543 122700 0.02 56
240 1049 125434 0.04 91
300 1429 128175 0.05 110
360 1632 131115 0.05 113
420 2528 128741 0.09 184
480 1285 131016 0.04 91
540 571 123495 0.02 57
600 462 125451 0.02 44
660 405 130471 0.01 35
720 408 131304 0.01 34
1440 241 131914 0.01 23
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Determination of SN79 content in rat plasma samples after oral administration of SN79-di-
HCl to fed state Sprague Dawley rats (20mg/kg) - Rat 6 
 
Time (min) Drug Area IS Area Ratio Conc (ng/mL)
15 1565 133442 0.05 102
30 1481 134099 0.04 95
45 1693 131168 0.05 117
60 1654 132761 0.05 109
90 1595 125325 0.06 134
120 2295 133983 0.07 143
150 1739 131745 0.05 118
180 1454 130667 0.05 103
240 722 132806 0.02 52
300 716 130670 0.02 55
360 1355 132022 0.04 93
420 1665 141176 0.04 89
480 3199 136795 0.09 182
540 1894 132990 0.06 123
600 1508 138948 0.04 86
660 293 129547 0.01 28
720 299 135240 0.01 25
2160 116 120426 0.006 20
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Table B.8. Calibration curve for SN79-di-HCl for determination of SN79 content in 
gastrointestinal permeability samples from mucosal to serosal side 
 
Conc (ng/mL) Drug Area
5 1005
10 2220
25 4834
50 9405
100 19367
200 39844
500 99739
1000 198174
3000 601001
5000 1014556
 
Determination of SN79 content in permeability study from mucosal to serosal side in rat 
duodenum 
Time 
(min) Area 
Conc 
(ng/mL) 
Cumulative 
amt (ng) 
Accumulation  
(ug/cm2) 
Flux 
(ug 
cm-2 
min -1) 
Permeability 
(cm/min) x 
10-4 
Papp 
(cm/sec) 
X 10-6 
15 350 8 8 0.11 
0.038 1.5 2.53 
30 1238 12 13 0.19 
60 2926 20 24 0.34 
90 8923 50 58 0.82 
120 28628 147 165 2.34 
150 38434 196 243 3.44 
180 50155 254 340 4.81 
Papp – apparent permeability coefficient 
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Determination of SN79 content in permeability study from mucosal to serosal side in rat 
jejunum 
Time 
(min) Area 
Conc 
(ng/mL) 
Cumulative 
amt (ng) 
Accumulation 
(ug/cm2) 
Flux (ug 
cm-2 
min -1) 
Permeability 
(cm/min) x 
10-4 
Papp 
(cm/sec) 
x 10-6 
15 385 8 8 0.11 
0.035 1.4 2.33 
30 1291 12 14 0.19 
60 2342 17 21 0.30 
90 8658 49 56 0.79 
120 29130 150 167 2.36 
150 38759 197 244 3.46 
180 41901 213 299 4.24 
Papp – apparent permeability coefficient 
 
Determination of SN79 content in permeability study from mucosal to serosal side in rat 
ileum 
Time 
(min) Area 
Conc 
(ng/mL) 
Cumulative 
amt (ng) 
Accumulation 
(ug/cm2) 
Flux (ug 
cm-2 
min -1) 
Permeability 
(cm/min) x 
10-4 
Papp 
(cm/sec) 
x 10-6 
15 371 8 8 0.11 
0.037 1.5 2.47 
30 1249 12 14 0.19 
60 2313 17 21 0.30 
90 10098 56 63 0.89 
120 29334 151 169 2.40 
150 41450 211 259 3.67 
180 45012 228 319 4.51 
Papp – apparent permeability coefficient 
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Table B.9. Calibration curve for SN79-di-HCl for determination of SN79 content in 
gastrointestinal permeability samples from serosal to mucosal side 
 
Conc (ng/mL)Drug Area
5 945
10 2324
25 6962
50 9261
100 23568
200 43502
500 94811
1000 150435
3000 283169
5000 982640
 
Determination of SN79 content in permeability study from serosal to mucosal side in rat 
duodenum 
Time 
(min) Area 
Conc 
(ng/mL) 
Cumulative 
amt  
(ng) 
Accumulation 
(ug/cm2) 
Flux 
(ug 
cm-2 
min -1) 
Permeability 
(cm/min) x 
10-3 
Papp 
(cm/sec) 
x 10-5 
15 13202.79 137 137 1.94 
0.246 0.98 1.64 
30 21894.03 188 215 3.05 
60 42196.94 306 371 5.25 
90 82878.03 542 668 9.46 
120 108782.3 693 927 13.13 
150 202969.4 1240 1613 22.83 
180 314304.9 1887 2508 35.50 
Papp – apparent permeability coefficient 
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Determination of SN79 content in permeability study from serosal to mucosal side in rat 
jejunum 
Time 
(min) Area 
Conc 
(ng/mL) 
Cumulative 
amt (ng) 
Accumulation 
(ug/cm2) 
Flux (ug 
cm-2 
min -1) 
Permeability 
(cm/min) x 
10-3 
Papp 
(cm/sec) 
x 10-5 
15 18639 169 169 2.39 
0.259 1.04 1.73 
30 21457 185 219 3.10 
60 38797 286 357 5.05 
90 81653 535 663 9.39 
120 107092 683 918 12.99 
150 213606 1302 1674 23.69 
180 328157 1967 2599 36.79 
Papp – apparent permeability coefficient 
 
 
Determination of SN79 content in permeability study from serosal to mucosal side in rat 
ileum 
Time 
(min) Area 
Conc 
(ng/mL) 
Cumulative 
amt (ng) 
Accumulation 
(ug/cm2) 
Flux 
(ug cm-2 
min -1) 
Permeability 
(cm/min) x 
10-3 
Papp 
(cm/sec) 
x 10-5 
15 15775 152 152 2.16 
0.241 0.96 1.61 
30 23728 199 229 3.24 
60 42074 305 375 5.31 
90 83045 543 674 9.55 
120 100895 647 887 12.55 
150 210115 1282 1651 23.37 
180 303398 1824 2449 34.67 
Papp – apparent permeability coefficient 
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Table B.10. Metabolic stability of SN79 incubated as SN79-di-HCl in rat liver microsomes. 
  
Time (min) Area % Remaining Average SEM
88776 100
87414 100
84644 100
50107 56.4
50321 57.6
50238 59.4
40002 45.1
40198 46.0
40015 47.3
30549 34.4
30076 34.4
30478 36.0
20004 22.5
22669 25.9
22538 26.6
6276 7.1
6384 7.3
6181 7.3
1070 1.2
1023 1.2
1032 1.2
90
0
0.03
0.02
0.03
0.09
0.02
0.02
100
57.8
0
10
15
30
45
60
46.1
34.9
25.0
7.2
1.2
 
Percent remaining = (area at time t×100)/area at time zero; SEM = standard deviation/average 
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